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The onset of immune response against microbial stimuli activates induction of 
many anti- inflammatory genes and ISGs for effective clearance of the pathogen.  This 
response includes transcriptional activation of several non-coding transcripts such as 
miRNAs and long non-coding RNAs (lncRNAs). LncRNAs constitutes the largest class of 
non-coding genome and are arbitrarily described as transcripts greater than 200 base pairs. 
Similar to protein coding mRNAs, lncRNAs are RNA polymerase II transcripts and 
undergo mRNA processing such as capping, splicing and polyadenylation. In recent years, 
high throughput sequencing has enabled an in-depth exploration of the human genome and 
subsequent discovery of lncRNAs. Several studies have highlighted the crucial role of 
lncRNAs in many biological processes including as regulators of gene expression as well 
as molecular effectors of host-pathogen driven immune responses. To date, majority of 
lncRNAs have been studied in murine models with limited understanding in human cells. 
In order to elucidate the role of lncRNAs in human immune cell regulation, the goal of this 
thesis is to identify and characterize novel lncRNAs critical to host-pathogen innate 
immune responses. RNA sequencing in LPS, IAV and HSV stimulated cells revealed 
lncRNA LUCAT1 as most differentially regulated lncRNA. CRISPR-cas9 and shRNA 
mediated depletion of LUCAT1 showed enhanced IFN-I genes signature, which was 
suppressed upon overexpression of LUCAT1. Additionally, LPS stimulated hDCs showed 
enrichment of LUCAT1 in the nucleus and its association with the chromatin markers. 
Further, LUCAT1 depletion contributed to enhanced occupancy of transcriptional 
coactivators at the promoters of IFN-I genes. Global identification of RNA associated 
 x 
proteins revealed LUCAT1 association with STAT1 in the nucleus thus emphasizing its 
role in transcriptional regulation of Type I IFN genes in inflammatory responses. This 
thesis furthers the understanding about the molecular factors affecting immune regulation 
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Preface to Chapter I 
 
This chapter contains introduction for innate immune pathways that have been studied in 
the context of lncRNA LUCAT1 regulation of inflammatory responses.  
This chapter also provides a detailed overview of lncRNA, classification and functions 





1.1 Overview of Innate immune system and inflammatory response 
The mammalian immune system is a result of continuous evolutionary selection to 
cope with the threat exerted by a diverse group of invading pathogens. The immune 
systems can be broadly categorized into adaptive immune system and innate immune 
system, with a detailed focus on the latter here. Innate immune system is the primary line 
of defense evolved under selective pressure to adapt to pathogens. In contrast to adaptive 
immunity, which develops by clonal selection from an array of activated lymphocytes, the 
innate immune system is the first line of defense in our body and is mainly composed of 
germline encoding receptors expressed on phagocytic myeloid cells such as macrophages 
and dendritic cells (DCs). Previously, the innate immune function was believed to be a 
non-specific immune response limited to phagocytosis of foreign microorganisms. It is 
now understood that the innate effector cells express Pattern Recognition Receptors (or 
PRRs), which recognize and bind to a diverse group of conserved molecular protein 
features on the pathogen known as Pathogen Associated Molecular Patterns (PAMPs). This 
binding activates a cell signaling cascade within the innate immune cells. which is then 
relayed to adaptive immune system. The PRRs are specialized in recognizing specific non 
self-antigens to avoid damage to host cells and tissues. When self-antigens are released as 
a consequence of cell death, they come under the surveillance of immune response and are 
recognized as Danger Associated Molecular Patterns (DAMPs), following which an auto 
inflammatory response is triggered. Innate immune pathways are equipped with several 
distinct classes of PRRs including but not limited to Toll-like receptors (TLRs), RIG-I like 
 4 
receptors (RLRs), cytosolic DNA sensing receptors, NOD-like receptors (NLRs), AIM-2 
like receptors (ALRs) and C-type lectin receptors (CLRs) for sensing PAMPs from diverse 
microbial sources. In the following sections, TLRs and cytosolic nucleic acid sensing PRRs 
have been described in detail.  
 
1.2 Toll-like Receptor pathways and Cytosolic PRRs 
 
Toll like receptor (TLR) pathways are one of the first and most well characterized 
germline encoded receptors in innate immunity.  TLRs were first discovered and 
characterized in drosophila as an innate immune regulator in response to fungal infections 
[1]. Following the discovery of drosophila Toll receptors, human and mouse homologs of 
Toll receptor were identified that were capable of eliciting pro inflammatory gene signature 
in response to microbial ligands [2, 3]. TLRs are widely expressed on dendritic cells and 
macrophages and non-immune cells such as fibroblasts and epithelial cells [4]. TLRs are 
synthesized in endoplasmic reticulum (ER) and are then transported to be expressed at 
various locations in the cell including plasma membrane, endoplasmic reticulum, 
endosomes, lysosome or endolysomes to recognize various components of bacterial and 
virus pathogens inside and outside the cell [5]. At present, 10 members of TLR family in 
human and 13 TLRs in mouse have been identified. All TLRs are structurally similar and 
contain a horseshoe like ectodomain with leucine rich-repeats (LRRs) for receptor ligation, 
a transmembrane domain and a cytoplasmic Toll/IL-1 receptor (TIR) domain for signal 
transduction. TLRs are type 1 integral member glycoproteins and is a part of the IL-1 
receptor protein superfamily attributable to its 200 amino acid intracellular domain with 
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the IL1 Receptor (IL-1R)[5]. All TLRs signal through TIR domain adapter proteins such 
as MyD88 or TRIF to culminate activation of NF-κB , IRF3 and MAP Kinases and 
regulation of inflammatory cytokines. Although, TLR mediated signaling converges at 
various pivotal checkpoints, TLRs have evolved to recognize and bind to a myriad of self 
and non-self-immuno-stimulatory ligands. Details of each TLR, respective ligand and 
adapter protein in the pathway leading to downstream immune signaling and gene 
transcription has been provided below. 
Signal transduction events leading to induction of inflammatory gene transcription 
commences by ligand sensing and homo or hetero dimerization of TLRs, to recruit TIR 
domain adapter proteins such as myeloid differentiation primary-response protein 88 
(MyD88), TIR domain-containing adapter protein (TIRAP)/Mal, TIR-domain-containing 
adaptor protein inducing interferon-β (TRIF/TICAM1) and TRIF-related adaptor molecule 
(TRAM/TICAM2). MyD88 mediated signaling is used by all TLRs with the exception of 
TLR3 and endosomal TLR4, and TIR domain interaction between TLR and myD88 
facilitates linking of downstream kinases, interleukin-1 receptor-associated kinase (IRAK) 
family [6].  This binding facilitates the activation of downstream kinases known as 
interleukin-1 receptor-associated kinase (IRAK). The kinase activity of IRAK1 and IRAK4 
is crucial for advancement of NF-κB signaling pathway as evident by loss of pro-
inflammatory cytokines and increased propensity to infections in IRAK4 deficiency[7]. 
Contrarily, IRAK family member, IRAK-M exert inhibitory effects on signaling by 
restricting disassociation of IRAK1 and IRAK4 from MyD88 suggestive of their negative 
regulatory roles [8]. Upon stimulation, IRAK1 and IRAK4 are phosphorylated followed 
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by disengagement from MyD88 triggering activation of tumor necrosis factor receptor-
associated factor 6 (TRAF6) [6]. In conjugation with Ubc13 and Uev1A, TRAF6 functions 
as a E3 ligase, owing to its N-terminal RING domain, to promote K63 ubiquitin-dependent 
activation of transforming growth factor-β-activated protein kinase 1 (TAK1). 
Subsequently, TAK1 activates the IKK complex in conjugation with TAB1, TAB2 and 
TAB3 to stimulate NF-κB targeted proinflammatory genes such as IL6, TNF-α  [9]. 
1.2.1 Toll Like Receptor 4 
TLR-4 is a transmembrane protein, ubiquitously expressed on the cell surface of 
majority of cell types in the body. TLR4 primarily recognizes gram-negative bacterial outer 
wall component Lipopolysaccharide (LPS) and other plant, bacterial and virus components 
to activate intracellular signaling [10, 11]. The non-covalent interaction of TLR4 with 
Myeloid Differentiation 2 (MD2) adaptor protein is required for this activity [11]. 
Extracellular LPS forms large aggregates in aqueous environments in circulation and is 
bound to accessory protein, LPS binding protein (LBP). This complex is recognized by the 
CD14 and presented to TLR4-MD2 complex, which in turn activates downstream signal 
transduction. The binding of LPS to the adaptor protein is critical to enabling its detection 
by the receptor to elicit the downstream cytokine release [9]. Following TLR4 binding to 
LPS , GTPase, dynamin mediated endocytosis of the complex is induced, which is 
disrupted in presence of dynamin specific inhibitors [12]. CD14 adaptor is associated with 
aiding this internalization, although CD-14 independent translocation of the TLR4-MD2 
complex has also been described [11] 
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 In contrast to other type-I IFN inducing PRRs that are primarily cytosolic nucleic 
acid sensors, TLR4 is an extracellular receptor and can induce IFN-I gene program in 
response to LPS. Further, TLR4 is also unique in its capability to signal through two 
distinct pathways- MyD88-TIRAP dependent activation of proinflammatory cytokines and 
a delayed TRIF-TRAM mediated induction of Interferon β (IFN-β) [13, 14]. Ligand 
binding initiates, TLR4 induction, aggregation and dimerization of MD2/TLR4 complex 
on the cell surface. At the plasma membrane, the TIR domain of TLR4 homodimer links it 
to downstream adapters MyD88 and MAL/TIRAP to recruit and activate IRAKs, TRAF6 
and TAK1 mediated activation of NF-κB  dependent gene program. Endosomal TLR4 
signals via TRIF and TRAM to activate TBK1 mediated induction of TRAF3 and IRF3 
subsequently activating IFN-β genes [14, 15]. In addition, vesicular endosomal TLR4 leads 
to TRIF mediated phosphorylation of IRF3 and subsequent upregulation of tyep1-I IFN 
genes specifically IFN-β [16].  
 8 
 
Figure 1.1 TLR4 signaling pathway. Surface receptor TLR4 and co-receptors 
MD2 and CD14 binds to serum LPS transported by LBP to activate a MyD88, IRAK1/4 
and TRAF6 mediated activation of TAB2/3 and TAK1, which in turn activate NEMO 
releasing IKKα and IKKβ for activation of p50/p65 and its nuclear translocation for 
induction of NFκB dependent genes. Upon LPS binding, TLR4 is internalized in the 
endosomal compartment and involves recruitment of adapters TRIF and TRAM, activating 





1.2.2 Toll Like Receptor 2 
TLR2 is exclusively expressed on the cell surface of antigen presenting cells and 
endothelial cells and functions as a hetero dimer in conjugation with TLR1 and TLR6. The 
ability of TLR2 to dimerize with TLR1 and TLR6 enables recognition of a broad range of 
microbial ligands. Cooperation between TLR2 with constitutively expressed TLR6 
coordinate macrophage activation by recognition of lipopeptides from gram positive 
bacteria and yeast cell wall component, zymosan, secreted modulin from S. aureus in the 
macrophage phagosome [17]. Additionally, tumor necrosis factor -alpha (TNF-α) 
induction by TLR2 can only take place in conjugation with TLR6. TLR2 can also recognize 
bacterial lipopeptide independent of its association with TLR6 [18]. Association of TLR2 
and TLR1 is crucial for recognition of triacyl lipopeptides and soluble factors released 
from Neisseria meningitidis. Mice lacking TLR1 show impaired production of 
inflammatory cytokines, although TLR1 and TLR6 are homologous and TLR6 can 
compensate for TLR1 loss [13]. Both TLR2/TLR1 and TLR2/TLR6 hetero trimeric 
complexes utilize MyD88 and TIRAP/MAL to activate NF-kB dependent inflammatory 
gene response.  
 
1.2.3 Toll Like Receptor 5 
TLR-5 recognizes bacterial flagellin, primary component of flagella that extends 
outwards from the cell wall of gram-negative bacteria and signaling through TLR5 only 
requires adapter molecule MyD88. Flagellin genes are highly conserved across diverse 
gram-negative bacteria and is the primary immune-stimulatory molecule. Flagellin helps 
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bacterium to propel forward in an aqueous medium and also allows anchoring to host cell 
[9].  
1.2.4 Toll Like receptor 3 
TLR3 is an endosomal receptor and is predominantly expressed on dendritic cells 
[19, 20]. Interestingly, TLR3 differs from other TLRs by lacking a conserved proline 
(proline-712) residue required for downstream signaling. Substitution of this proline 
residue with histidine in TLR4 and other TLRs completely abolishes their signaling 
capability, thus suggesting a different signaling pathway downstream of TLR3 receptor. 
TLR3 specifically activates TRIF-TRAM dependent pathway unlike other endosomal 
receptors TLR 7, 8 and 9 which require MyD88 for signal transduction. [21]. TLR3 is a 
sensor of dsRNA produced as an intermediate in RNA synthesis or as a byproduct produced 
by replication of DNA viruses. Upon sensing of viral dsRNA, TLR3 activates specific 
dsRNA dependent protein kinases to induce a strong type-I IFN response. This pathway 
can be induced using synthetic dsRNA analog, polyinosinic-polycytidylic acid [poly (I:C)] 
which is widely used to study TLR3 signaling. 
 
1.2.5 Toll Like receptor 7/8 
TLR 7 and 8 are closely related endosomal receptors that have MyD88 adapter for 
downstream signaling. TLR7 and TLR8, in addition to ssRNA, recognize free guanosines 
and free uridines molecules respectively [22]. TLR7 is predominantly expressed on 
plasmacytoid DCs and B cells and can be induced in low expressing immune and non-
immune cells such as macrophages, keratinocytes and hepatocytes upon virus 
 11 
infections[23, 24]. On the other hand, TLR8 is highly expressed in myeloid cells such as 
macrophages and DCs [25]. Viruses such as vesicular stomatitis virus (VSV), Influenza 
virus, HIV-1, hepatitis B virus, and HCV as well as synthetic guanine-rich RNA analog, 
R848 can transcriptionally upregulate TLR7 expression and aggregation on endosomal 
compartment. Unlike TLR8 and TLR9 that are present in dimeric state in resting phase, 
TLR7 is induced and dimerized upon ligation of ssRNA [24]. 
 
1.2.6 Toll Like receptor 9 
TLR 9 is an endosomal DNA sensing receptor that preferentially binds to cytosine-
phosphate guanine dideoxynucleotide (CpG) motifs in bacterial  and viral genomes [26]. 
TLR9 recognizes viral DNA from cytomegalovirus (CMV), Herpes Simplex Virus-1 
(HSV-1) [27], HSV-2 [28] and adenovirus [29] in plasmacytoid dendritic cells. Mice 
lacking TLR9 receptor exhibit high viral titers and partial abrogation of type-1 IFN 
response and decreased survival in mouse CMV infections [30]. Unlike cytosolic nucleic 
acid receptors, TLR9 mediated sensing of viral DNA is independent of replication events 
and occurs upon endocytosis and uncoating of virus particles [31, 32].  
1.2.7 RIG-I like receptors (RLR) 
Retinoic acid inducible gene-1 (RIG-I) are conserved intracellular receptor for 
cytosolic RNA and are encoded by gene DDX58, is a DExD/H box RNA helicase identified 
as an [33]. The RLR receptor family also includes melanoma differentiation-associated 
gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP-2), all of which contain 
a DExD/H box RNA helicase domain (DEAD domain) and a C-terminal repressor domain 
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(CTD). Unlike LGP-2, RIG-I and MDA5 contain a N-terminal caspase activation and 
recruitment domain (CARDs) domain and recognize various forms of RNAs in the cytosol 
[34]. RIG-I binds to small 5’triphosphate RNA and ssRNA whereas MDA5 specifically 
ligates to dsRNA longer than 20bp enabling its oligomerization on the RNA molecule. 
Additionally, RIG-I also get activated by uncapped 5’ diphosphate (PP) groups and 5’ 
unmethylated nucleotide at the 2’-O position [35, 36]. RNA released as a consequence of 
virus replication by Sendai Virus (SeV), Influenza A. virus(IAV), Hepatitis C virus (HCV), 
Vesicular stomatitis virus (VSV) and Respiratory Syncytial Virus (RSV) is detected by 
RIG-I. MDA-5 recognizes encephalomyocarditis virus (EMCV), coxsackie B virus (CBV) 
and polio virus to activate Interferon Regulatory Factor3 (IRF3) and IRF7 mediated 
transcriptional activation of type-I IFN response via ER localized mitochondrial antiviral 
signaling protein (MAVS) [37]. The binding specificity of RLR receptors toward the 
3’phosphate groups of viral RNA enables them to distinguish between self and non-self 
RNA antigen[34]. 
1.2.8 Cytosolic DNA sensors 
In eukaryotic cells, DNA is localized in the nucleus however, presence of DNA in the 
cytosol or endosomes of the cells is immuno-stimulatory, activating Type-I pathway. It is 
now well understood that unmethylated CpG DNA from pathogens is recognized by 
endosomal TLR9 [26].  Double stranded DNA in the cytosol may also be a result of virus 
replication, DNA from intracellular bacteria, leakage of endogenous DNA (e.g. during cell 
death processes) and exogenous DNA from cellular debris that is endocytosed in the 
lysosomes [38]. The presence of DNA in cytosol activates nucleic acids sensors to elicit an 
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immune response. For instance, Mycobacterium tuberculosis infection results in release of 
bacterial DNA in the cytosol that activates the type-I IFN pathways, contributing of 
bacterial pathogenesis [39]. Similarly, proteasomal degradation of viral capsid of some 
viruses such as HSV-1 and CMV in the cytoplasm releases the viral DNA in the cytoplasm 
for immune sensing [40]. 
 Immune sensing of cytosolic DNA from various sources results in the induction of 
type-I interferon dependent gene program. The key pathway components to mediate this 
response are cGAMP synthetase (cGAS), a cyclase enzyme which senses the DNA and 
activates Stimulator of Interferon Genes (STING), an adaptor protein central to the 
transduction of the signal to downstream kinases [38]. Structural analysis showed cGAS 
binding to sugar phosphate backbone of DNA to activate STING-IRF3 mediated IFN-β 
expression [41].   Macrophages and dendritic cells derived from cGAS knock out mice 
showed impaired antiviral cytokine response in transfected DNA or DNA virus infection 
conditions [42]. STING is anchored to the ER by its N-terminal transmembrane domains 
in resting state. Upon binding of cytosolic DNA to cGAS,  a conformational change in the 
catalytic site stimulates the ATP and GTP dependent synthesis of cyclic-di-GMP-AMP 
(cGAMP). This leads to colocalization of STING with TBK-1 in the perinuclear punctate 
foci. Further, the C-terminal cytosolic domain of STING enables assembly of IRF3 close 
to TBK1, allowing TBK-1 dependent phosphorylation of IRF3, followed by IRF3 
dimerization and nuclear translocation [41]. ZBP-1 or DAI is another example of cytosolic 
DNA sensor that signals through STING-TBK1-IRF3 pathway to activate type-I IFN 
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response. Although, DAI detects cytosolic DNA from HSV-1 and cytomegalovirus 
(CMV), it functions in a cell specific manner to activate IFN-β [38].  
 
1.3 Signal Transduction Pathways in Innate Immune Signaling 
Engagement of PAMPs by PRRs activate signaling cascade for the induction of 
inflammatory gene program. The ligation of both cytosolic and cell surface receptors leads 
to activation of cytokines by multitude of signaling cascades described below. 
1.3.1 NF-κB Signaling 
NF-κB signaling is central to TLR mediated innate immune responses and 
contributes to activation of several proinflammatory genes as well as inflammasome 
assembly and activation. Structurally, TLRs have three distinct domains, an extracellular 
leucine rich repeat (LRR) domain for PAMP recognition, a transmembrane domain and an 
intracellular Toll/IL-1 Receptor (TIR) domain to execute signal transduction events . NF-
κB was discovered in the nucleus of B cells associating with the conserved sequence of κ 
light chain genes and therefore was named NF-κB after its location and cell type its was 
found, i.e. nuclear factor – binding near the κ light chain in B cells [43]. NF-κB is a dimeric 
complex that is rapidly induced upon pathogen sensing to activate the transcription of a 
broad range of inflammatory genes. The NF-κB family consists of five proteins, p65/RelA, 
p50 (processed from precursor protein NF-κB1/p105), p52 (processed from precursor 
protein NF-κB2/p100), RelB and c-Rel that bind in groups of dimers to the conserved, 
semi-palindromic sites on the promoters and enhancers of target genes. These NF-κB 
factors utilize their Rel homology domain to associate with DNA at the κB sites of the 
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promoters of target genes [44].  The canonical NF-κB pathways are activated by release 
and binding of heterodimers- p50:p65 and p52:RelB In contrast to the repressive activity 
of homodimers [9, 43].  
In resting cells, NF-κB is sequestered in the cytoplasm by the association with 
inhibitory proteins known as Inhibitors of kappa B (IκB) family, which are degraded via 
post translational serine phosphorylation to release NF-κB and rapidly turn on gene 
transcription [45]. For canonical NF-κB activation, a kinase protein complex, IKK 
specifically phosphorylates IκB proteins at serine residues, enabling NF-κB release, 
nuclear translocation, binding to chromatin at target gene loci and induction of gene 
transcription. Inactive holoenzyme IKK comprises of kinases, IKKα and IKKβ subunits 
bound to non-catalytic regulatory subunit IKK gamma (also called NF-kappa-B essential 
modulator (NEMO)). Receptor ligation events initiate ubiquitination and phosphorylation 
of Nemo and IKKα /IKKβ respectively for NF-κB  activation and binding to κB sites on 
the chromatin. [43].   
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Figure 1.2 TLR and NFκB signaling pathways. Upon TLR ligation with respective 
ligands, TLRs recruits specific TIR adapters MyD88, TIRAP, TRAM and TRIF for 
activation of TRAF and IRAK proteins which in turn activate NEMO and subsequent 
degradation of IKB releasing NFκB for nuclear translocation and activation of 
proinflammatory genes, TLR3 and TLR 4 uses TRIF for activation of TBK1 followed by 
IRF3 phosphorylation and dimerization, nuclear localization and induction of type-1 IFN  





1.3.2 Type 1 Interferon signaling 
Type-1 IFNs are a group of signaling polypeptides that are released in response to 
an immune event in cells. In human, this large family of IFN-I consists of 13 isoforms of 
IFN-α (alpha), one isoform of IFN-β (beta), IFN-κ (kappa), IFN-ε (epsilon) , IFN-ω 
(omega), and IFN-ζ (zeta, also known as limitin). IFN-δ (delta), IFN-τ (tau) are found in 
mouse cells exclusively [46]. These cytokines are produced at different levels and in a cell 
specific manner, with IFN-α and IFN-β being predominantly expressed by majority of 
immune cells, IFN-κ (kappa) expressed in keratinocytes and IFN-ε (epsilon) in placenta 
[47].  IFN-α and IFN-β are induced during host-pathogen interactions and function to elicit 
immune response in an autocrine and paracrine manner by binding to the heterodimer 
receptor (IFNAR 1/2) for effective induction of immune response and clearance of 
pathogen. Additionally, IFN-I cytokines also function to activate adaptive immunity and 






Figure 1.3 Type I Interferon pathway. Type 1 interferons bind to the heterodimeric cell 
surface receptor IFN-alpha/beta R1 and IFN-alpha/beta R2 to activate associated tyrosine 
kinases, TyK2 and Jak1 respectively. These kinases phosphorylate STAT proteins 
initiating its homo or hetero dimerization. Activated STAT-1 homodimers associate with 
IRF9 to form an ISGF3 complex which translocates to the nucleus to bind to ISRE elements 
at the promotors of ISGs. STAT1/STAT2 heterodimers translocate to the nucleus to bind 








IFNAR 1/2 receptor contains two chains IFNAR 1 and IFNAR2, where IFNAR2 
binds to the ligand and both are required for downstream signaling. Engagement of 
heterodimerized IFNAR receptor upon IFN binding leads to receptor dimerization 
followed by auto and trans phosphorylation by receptor associated protein tyrosine kinases 
Janus Kinase 1(JAK1) and tyrosine kinases (TYK2) which are associated with  IFNAR2 
and IFNAR 1 chains respectively.  In turn, JAK1 and TYK2 phosphorylate transcription 
factor Signal Transducer and Activator of transcription (STAT1 and STAT2)[48]. This 
modification is succeeded by their translocation to the nucleus for induction of ISGs. 
Tyrosine phosphorylated STAT1/STAT2 dimer associates with Interferon Regulatory 
Factor, IRF9 to form a trimeric complex. This trimer, also known as IFN stimulated gene 
factor 3 (ISGF3) binds to Interferon Stimulated Response Elements (ISRE) at the 
promoters of several ISGs to transcriptionally induce their expression. On the In contrast, 
STAT1 and STAT2 homodimers translocate to the nucleus to bind to associate with the 
Gamma activates sequence (GAS) elements to activate a distinct class of ISGs which play 
role in anti-viral immune responses [48]. Although, IFN-I play protective roles and are 
crucial in acute infections to clear pathogens, unrestricted activation of IFN-I can result in 
chronic inflammation and auto immune disorders [50]. Therefore, fine tuning of IFN-I 
signaling is essential to minimize tissue damage and restoration of homeostasis [51]. 
It is now well understood that basal levels of IFN-I cytokines are produced in 
response to commensal pathogens. This response is adequate to maintain low basal 
responses and engagement of IFN-I signaling by expression of signaling molecules such 
as STAT1, STAT2, and IRF9. In absence of pathogenic stimuli, several factors orchestrate 
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to restrict an inflammatory response by suppression ISG transcription, translation and 
activation [49]. 
 
1.4 Negative Regulators of Immune Cell Signaling 
1.4.1 Negative regulation of Type-1 interferon signaling 
 
Type 1 IFN signaling lies at the core of host-pathogen response, and almost all cells 
are capable of transcriptionally activating ISG expression, which lies downstream of 
IFNAR receptor. Activation of immune response is a temporary event, and is induced 
immediately upon pathogen sensing to establish protective immunity. The myriad of 
pathogen sensing receptors is capable of detecting diverse PAMPs, and cross-talk at 
various levels of signaling ensuring an effective Type-I IFN response for pathogen 
clearance. This is carried out by TLR 3,4,7,8,9, and cytosolic nucleic acid sensing 
receptors. Cellular responses to microbial stimuli takes effect in a cell and tissue specific 
environment and PAMP specific manner to protect the host.  
The transcriptional activation of immune gene signature resulting in release of 
cytokine and effector molecules is tightly orchestrated to limit tissue damage and to attain 
homeostasis. Proinflammatory effects of Type-I signaling events are quite deleterious to 
the infected and surrounding cells and can result in systemic tissue damage and auto-
inflammatory conditions known as Interferonopathies[52]. Aberrant activation of IFN-I 
signaling or a loss in containment can result in chronic inflammatory disorders such as 
lupus erythematosus (SLE), Sjo ̈gren’s syndrome, rheumatoid arthritis and Aicardi– 
Goutières syndrome (AGS)[52-54]. Therefore, to counterbalance the events of IFN-I 
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signaling and subsequent activation of immune gene program, several negative regulators 
are also co-induced. Negative regulators of Type-I signaling execute at various levels of 
the pathways targeting PRRs, signaling pathways and transcriptional events leading to ISG 
expression, to ensure proper immune suppression and attainment of homeostasis.   
 
1.4.2 Negative regulators of PRRs 
Several studies report negative regulation of PRRs by direct binding to Ubiquitin 
ligase proteins, followed by proteasomal degradation. There are several E3 protein ligases 
involved in down regulating TLR contributing to IFN-I signaling. E3 ubiquitin ligase ring 
finger protein 216 (RNF216) can bind to TLR3, TLR 4 and TLR9 and activate their 
proteasomal degradation [55]. RNF125 and E2 enzyme ubiquitin conjugating enzyme H5 
(Ubch5) are induced by IFN and ubiquitinate cytosolic RLRs, RIG-I, MDA-5 and MAVS 
for inducing their proteasomal degradation. RNF125 depleted cells showed enhanced IRF3 
and IFN0I production upon SeV stimulation.[56]. Similarly, RNF122 mediated 
ubiquitination at K115 and K146 residues as well as K48 ubiquitination by IFI35, targets 
RIG-I for proteasomal degradation, thus limiting RNA virus mediated IFN-I signaling. [57, 
58].  
Similarly, IFN-I inducible IFIT1(ISG56) have been reported to inhibit Human 
Papilloma virus, hepatitis C virus (HCV) replication and translation and additionally 
associates with STING to block its interaction with adapter proteins MAVS or TBK-1[59, 
60]. Lin et al demonstrated inhibition of RIG-I by anti-apoptotic protein (A20) by blocking 
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RIG-I mediated IRF3 phosphorylation, homo-dimerization and DNA binding activity, thus 
enhancing vesicular stomatitis virus replication [61].  
 
1.4.3 Negative regulators of signaling molecules 
Protein tyrosine phosphatases (PTPs) are critical regulators of phosphorylation during 
JAK-STAT signaling in IFN-I responses. Src homology phosphatase 1 (SHP1) and SHP2 
negatively regulate IFN-I signaling. SHP2, a SH2 containing protein tyrosine phosphatase, 
is ubiquitously expressed in cells and functions to protect the cells from cytotoxic effects 
of IFN-I cytokines. Murine MEFs cells with mutant SHP2 shows hyperactivation of 
STAT1 and increased phosphorylation of JAK1 specifically thus negatively regulating 
IFNγ mediated JAK-STAT1 signaling events [62]. Contrarily, SHP1 is primarily expressed 
in hematopoietic cells and is associated with the IFNAR1  subunit to specifically restricts 
JAK1 phosphorylation and downstream STAT1 activation thus affecting GAS element 
gene transcription [63].  
Other phosphatases such as protein-tyrosine phosphatase 1B (PTPB1) also known 
as PTTPN1 and T cell protein tyrosine phosphatase (TC-PTP; PTPN2) are closely related, 
display differential substrate specificity to regulate cytokine signaling. PTPB1, localized 
on the endoplasmic reticulum, can regulate IFN-I signaling by targeting JAK2 and TYK2 
and thus modulating the responses to IFNα and IFNγ [64, 65]. Additionally, PTPB1 can 
also  inhibit NF-κB and TLR3 activation downstream of TLR augmentation to suppress 
pro-inflammatory cytokine expression in both TRIF and MYD88 dependent manner [66]. 
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Nuclear localized PTPN2 suppresses phosphorylation events of and JAK1 and JAK3 
consequently dephosphorylating STAT1, STAT3 and STAT5α/β [64, 67]. 
The conserved superfamily of tripartite motif-containing (TRIM) proteins are 
induced by both Type-I and Type-II interferons. The Ring domain of TRIM protein is 
capable of associating with ubiquitin like proteins thus conferring to its E3 ubiquitin ligase 
function [68]. Ubiquitination by TRIM E3 ligases regulate IFN production by negatively 
regulating signaling molecules. TRIM 13 interacts with MDA5 to negatively regulate IFN-
I response against encephalomyocarditis virus (EMCV) and Poly IC[69]. Further 
knockdown studies show that TRIM13 positively regulated RIG-I activity suggesting a 
dual role of TRIM13 and a PRR specific function [69].  
Both RIG-I and MDA-5 can sense cytosolic RNA viruses to elicit an IRF3 
dependent cytokine response. Phosphorylation, dimerization and nuclear translocation of 
IRF3 is crucial for onset of Type-I IFN mediated ISG expression. TRIM 11 inhibits the 
activity of RIG-I induced expression of IFN-β and affects IRF3 phosphorylation and 
dimerization by associating with TBK1 to negatively regulate IFN-β production [70]. 
Similarly, TRIM26 negatively regulates IFN-β by targeting phosphorylated IRF3 
specifically in the nucleus for K48 ubiquitination mediated degradation thus limiting 
inflammatory responses of TLR3 and TLR 4 and cytosolic nucleic acid sensing pathway 
[71]. TRIM27, TRIM 38 and TRIM 28 have also been shown to attenuate IFN-I response 
by K48-linked ubiquitination of TBK-1, TRIF and sumoylation of IRF7 respectively, 
targeting them for degradation [72-74].   
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Suppressor of cytokine signaling 1 (SOCS1) is a potent inhibitor of cytokine 
signaling and mice deficient in SOCS1 display a systemic inflammatory gene signature 
contributed by both Type-I and Type-II signaling pathways. Attributed to enhanced IFN-I 
responses, SOCS1 deficient mice also show greater virus clearance capability [75, 76]. 
Additionally, SOCS1 also plays a role in TLR driven NF-κB  response, by interacting with 
adapter protein Mal downstream of TLR2 and TLR4 pathways. Upon associating with 
SOCS1, Mal is polyubiquitinated and subsequently degraded, thus restricting p65 mediated 
expression of NF-κB  dependent genes [77]. Therefore, SOCS1 is a potent regulator of 
both inflammatory and anti-viral immune response. SOCS1 deficiencies result in severe 
developmental and inflammatory malfunction. As eluded earlier, TBK-1 plays crucial role 
in anti-viral innate immune response in cytosolic nucleic acid sensing pathways. SOCS3 is 
essential for regulation of IRF-3 and IFN-β transcription by associating with TBK-1 and 
promoting its proteasomal degradation. During vesicular stomatitis virus (VSV) and 
influenza A virus strain A/WSN/33 (WSN) infections, SOCS3 binds to TBK1, 
sequestering it in the cytosol and catalyzing K48-linked polyubiquitination 
of TBK1 followed by proteasomal degradation [78]. Thus, both SOCS1 and SOCS3 limit 
IFN-I mediated anti-viral responses. 
A20 contains both, a deubiquitinase and a ubiquitin ligase domain and can inhibit 
TLR3 pathway. A20 functions by adding K48 ubiquitin chains on TRAF6 and RIP1, 
marking them for degradation causing LPS and TNF-α mediated hypersensitivity and 
inflammation in mice. Additionally, A20 also removes K63 chains on TRAF3 thus 
inhibiting its degradation required for activation of IFN-I signaling [79]. 
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1.4.4 Negative regulation of IFNAR receptor 
In order to ensure complete withdrawal of cytokine transcription and return to 
homeostasis, several proteins promote inhibition of heterodimer IFNAR (IFNAR1 and 
IFNAR2) receptor. IFNAR1 and IFNAR2 are associated with TYK2 and JAK1 
respectively for signal transduction upon receptor ligation. Binding of IFNα to IFNAR 
results in phosphorylation of IFNAR1 at Ser535, which is facilitated by the inducible 
expression of protein kinase D2 (PKD2). Upon phosphorylation, PKD2 mediates IFNAR1 
internalization, followed by E3 ubiquitin ligase, beta-TrCP2 (beta-transducin repeats-
containing protein 2) mediated ubiquitination and proteasomal degradation, thus down 
regulating JAK1-STAT pathway [80, 81]. Interestingly, phosphorylation dependent 
downregulation of IFNAR1 can be stimulated in a ligand independent manner by viral 
infection induced unfolded protein response (UPR) proteins. In absence of IFNAR 
interaction with IFNα, UPR also promotes Ser(535) phosphorylation of IFNAR1 by 
activation of casein kinase 1 alpha (CK1α) and PKR-like endoplasmic reticulum kinase 
(PERK) [51, 82]. 
In contrast to the IFNα-PKD2 induced proteolysis of IFNAR1, Ubiquitin Specific 
Protein 18 (USP18/ubp43) negatively regulates IFNAR signaling by specifically binding 
to IFNAR2 subunit prompting JAK1 displacement and inhibiting its binding. USP18 
deficient cells show increased and prolonged STAT1 phosphorylation, hyper-induction of 
STAT1 dependent ISGs and reduced viral load [83]. 
USP18 also changes binding affinity of IFNAR to IFNα by modulating its binding sites 
 26 
Additionally, isopeptidase activity of USP18 cleaves ISG15, a strongly induced ISG during 
IFNAR signaling and transcriptionally downregulates expression of ISG15 targeted anti-
viral genes [83-85]. 
 The function of Type-I interferon system is not only restricted to pathogen 
clearance by eliciting anti-viral immunity, but extends to other cellular processes such as 
proliferation, cell maturation and differentiation. The importance of negative regulation of 
IFN-I pathway is evident from studies showing exacerbation of lethality by excessive tissue 
damage in animals lacking mechanisms for abrogating these responses. Therefore, the 
existence of multitude of pathways for constraining interferon responses is justified. The 
key signaling regulators coordinate pathway function and orchestrate their impact in a 
temporal and dose dependent manner, with the objective of achieving pathogen clearance 
with minimal host tissue damage. LncRNAs have emerged as a novel set of molecular 
regulators influencing gene expression and function. Signaling regulation at the level of 
lncRNAs further provides a robust mechanism for fine tuning the activation, duration and 
sustenance of inflammatory pathways as discussed in the next section.  
1.4.5 Metabolic reprogramming during immune activation 
During an immune event, activated macrophages and dendritic cells counteract 
microbes and microbial products by phagocytosing and releasing microbe neutralizing 
cytokines and effector molecules. The initiation and progression of host-pathogen 
responses, not only activates immune pathways but also coregulates signaling transduction 
pathways involved in cell proliferation, tissue repair and development. In recent years, 
metabolic reprogramming is a crucial event that is activated in a of immune cells has 
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emerged to be one of the crucial events to be co-activated in a pathogenic response [86]. 
Metabolic pathways, in addition to functioning as ATP reservoir for general functioning of 
the cells, also regulate immune cell functioning by inducing metabolic reprogramming 
during immune activation[87].  
Warburg effect was initially discovered in cancer cells, which predominantly relies 
on ATP produced by switching from oxidative phosphorylation to glycolysis [88]. In 
addition to its role in cancer, the Warburg Effect is also  
central to understanding metabolic reprogramming in immune cells [89]. Similar 
observations were made in LPS activated neutrophils which showed enhanced glucose and 
oxygen consumption, characteristics consistent with glycolytic respiration.  Increased 
oxygen consumption in activated neutrophils results in enhanced production of reactive 
oxygen species, H2O2 required for neutrophil mediated killing [90]. Additionally, resting 
macrophages exhibit glycolytic respiration which is increased upon activation in 
conjugation with decreased oxygen consumption [91]. Upon activation, macrophage and 
dendritic cells undergo Warburg metabolic switch from OXPHOS to glycolysis resulting 
in rapid production of ATP and increased ROS production. TLR activation or IFN-I 
activated macrophages show increased lactate production and enhanced NADPH for 
increased ROS production which is used for destruction of microbes[90].  
Advancements in metabolomics studies have revealed extensive turnover of 
metabolites in immune activated macrophages.  Substrates in Kreb’s cycle in particular, 
Citrate,  mediates effector functions in promoting anti – inflammatory responses . TCA 
cycle intermediate, Citrate is generated by conversion of oxaloacetate to acetyl-CoA by the 
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enzyme citrate synthase in the mitochondria[92]. In activated macrophages, increased 
expression of citrate transporter, solute carrier family 25 member 1 (Slc25a1), transports 
citrate from the mitochondria to the cytosol, resulting in its cytosolic accumulation [93]. In 
presence of ATP, cytosolic citrate is converted back to oxaloacetate and acetyl-CoA by the 
enzyme ATP-citrate lyase (ACLY), thus generating acetyl groups required for acetylation 
of histones, thus modulating transcription of downstream genes [94]. Furthermore, the 
generation of acetyl CoA, as a result of breakdown of cytosolic citrate promotes metabolic 
switch in activated macrophages and dendritic cells by increasing lipid biosynthesis.  The 
increased glycolytic flux is mediated by TBK1, which enhances the association of 
glycolytic enzymes with the mitochondria [95]. Additionally, inhibition of fatty acid 
synthesis or blocking cytosolic transportation of citrate results in failure to activate DCs in 
LPS stimulated conditions. This decrease in fatty acid synthesis further reduces  ER and 
mitochondrial membrane expansion, followed by abrogated cytokine generation thereby 
impacting the induction of immune response [95]. 
Activation of TCA cycle is the primary source of production of many of the 
metabolites upregulated during an immune event. Succinate is a TCA cycle intermediate, 
which is increased during LPS challenge in macrophages [96]. Succinate production during 
LPA stimulation is a result of upregulation of glucose metabolism in contrast to TCA cycle 
mediated generation of succinate [90].  Succinate functions as a pro-inflammatory 
metabolite which mediates metabolic switch to glycolysis by stabilizing HIF-1a, thereby 
inducing IL-1b transcription [96]. 
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Itaconate was initially discovered in macrophages which showed increased levels 
of itaconate upon LPS stimulation, which is generated by decarboxylation of cis-aconitate 
as TCA cycle intermediate [97]. Soon, it was discovered that Itaconate production is 
mediated by the gene immune-responsive gene 1 (IRG-1), an ISG, which is highly 
inducible in activated macrophages [98]. Many early studies investigating immunological 
role of itaconate reported its ability to inhibit bacterial growth by altering their metabolic 
pathways , therefore making them more susceptible to immune attack [99]. However, a 
more global immunological role of Itaconate was established by studies performed in IRG1 
null murine models, showing exacerbated immune response during LPS challenge 
suggestive of its anti-inflammatory role [100].  
1.4.6 NRF2 and Immune function 
Nuclear factor erythroid 2 (NRF2) belongs to the cap n’ collar (CNC) family of 
transcription factors that functions to maintain homeostatic balance during oxidative stress 
and electrophilic stress in the cells. [101]Under resting conditions, NRF2 is inactivated by 
binding to an adapter protein of E3 ligase, KEAP1 (Kelch-like ECH-associated protein 1) 
in the cytoplasm. Post transcriptional modifications of KEAP1 targets it for degradation 
thus releasing NRF2. Upon activation, NRF2 translocates to nucleus to activate 
transcription of an extensive de-toxifying gene program by binding to the conserved 
antioxidant response elements (ARE) for neutralization of oxidative stress and inducing 
cyto-protection. In recent years, broader roles of NRF2 in regulation tumorigenesis, cell 
cycle homeostasis and inflammation and innate immunity were discovered.  
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In recent years, NRF2 has been studied in the context of inflammation and 
immunity, as it can activate induction of genes such as haemoxygenase 1 involved in tissue 
repair during inflammatory responses. Studies performed in NRF2 deficient mice, showed 
enhanced immune activation upon challenge with Streptococcus pnemoniae which 
corresponded with dysregulation in immune response resulting in enhanced lung tissue 
injury and an autoimmune phenotype. Similar observations were made in various 
inflammatory murine models such as sepsis, pleurisy and also reported to modulate subside 
inflammation in activated myeloid cells. Interestingly, dimethyl fumarate, compound 
clinically prescribed for multiple sclerosis, targets KEAP1, thereby activating NRF2. 
Given, the structural similarities between itaconate and fumarate, role of itaconate in NRF2 
activation was further explored. Cell permeable forms of itaconate, dimethyl itaconate and 
4-ocytl-itaconate, both were able to activate NRF2 by post transcriptionally modifying 
KEAP1. Therefore, elicitation of anti-inflammatory state by metabolic remodeling of cells 
and activation of NRF2 provides an interesting cross-section study metabolic-
immunoregulators of immune responses.   
 
1.5 Introduction to Non-coding RNA 
 
Up till late 1980s, the discovery of non-coding genome was collectively coined as 
“Junk DNA” due to its lack of sequence specificity, abundance of repeat elements in 
addition to low expression and pervasive transcription alternatively referred as 
“transcriptional noise” [102-104]. Amongst the first discoveries of putative lncRNAs, were 
non-conventional mRNAs, H19 and Xist, functioning epigenetically to regulate gene 
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expression. Biochemical experiments that confirmed the function of H19 as an RNA 
molecule showed no coding potential, premature translational termination signal and poor 
conservation between mouse and human [105, 106]. The notion of leaky transcription by 
RNA pol-II prevailed for a long time, thus challenging the existence of non-coding 
transcripts as functional lncRNAs. The recent advancement in high throughput sequencing 
technologies coupled with chromatin immunoprecipitation-sequencing (ChIP-Seq) have 
enabled a deeper understanding of human genome and subsequent discovery of functional 
non-coding mRNAs. It is now fairly understood that only <2% genome is encoded by 
protein coding genes [107] and more than 95% of the genes are transcribed into different 
classes of non-coding RNAs. In addition to RNA pol-II chromatin occupancy, lncRNAs 
are also characterized by the presence of active histone markers such as histone H3 lysine 
4 trimethylation (H3K4me3) and histone H3 lysine 36 trimethylation (H3K36me3) at the 
promoters and transcribed region of these non-coding genes respectively [108]. Human 
genome database of GENCODE (version 29) reports approximately 16000 lncRNA genes, 
that give rise to nearly 29000 lncRNA transcripts. Furthermore, the belief that protein 
coding genes are the essence of organismal complexity was disputed as it was discovered 
that complexity of organism was directly proportional to non-coding genes [109].  
LncRNAs share similar post transcriptional processing as the protein coding genes. 
Most lncRNAs are RNA polymerase II transcripts with exception of RNA pol III 
transcripts such as 7SL RNA genes [110]. Additionally, similar to protein coding genes, 
lncRNAs are 5’ capped with 7-methyl guanosine and are 3’ polyadenylated. LncRNAs 
lacking poly A tail are stabilized using other mechanisms such cleavage with RNAseP P 
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to generate mature ends, capping by snoRNP complexes or formation of circular molecular 
structure[111]. In contrast to protein coding mRNAs, lncRNAs have fewer, but longer 
exons and are expressed at low levels in a cell and tissue specific manner. As the name 
suggests, lncRNAs lack protein coding potential however few reports have suggested 
transcription of small protein coding ORFs within a lncRNA [112]. Till date, several types 
of long and short non-coding RNAs have been described in literature such as rRNA, tRNA, 
small nucleolar RNAs and various short RNAs such as miRNA, endogenous siRNAs and 
piRNAs. This thesis focuses on the long-non-coding RNAs in human immune cells.  
 
1.5.1 Identification of lncRNAs.  
Prior to advancements in deep sequencing technologies, sanger sequencing was the 
gold standard for DNA sequencing. Succinctly, sanger sequencing required polymerase 
based amplification of cDNA with 2′-deoxynucleotides (dNTPs) and 2′,3′-
dideoxynucleotides (ddNTPs) in the reaction. Incorporation of fluorescent labelled 
ddNTPs terminates the extension reaction thus creating cDNA fragment with varying 
3’ends which can then be detected in one single reaction. Sanger sequencing requires 
amplification of cDNA sequencing by bacterial cloning which proves to be laborious and 
highly ineffective.   
However, sanger sequencing presented several limitations to accurately identify 
and curate lncRNA database. Firstly, non-specific primer binding and secondly, secondary 
structure in DNA posed problems in accurate sequencing. Thirdly, sanger sequencing 
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proves to be highly cost ineffective which discourages for its use for high throughput 
sequencing.  
Microarrays 
Microarrays are the most common technology to survey genes, especially low 
expressed non-coding RNAs such as miRNAs and lncRNAs. Tiling microarrays use 
overlapping probes spanning the entire length of genome for unbiased genome wide 
analysis. Each microarray contains thousands of spots that are labelled with several probes 
per spot and is complimentary against one DNA sequence, therefore amplifying the signal 
for low expressed transcripts[113]. Although, use of tiling microarrays have resulted in 
discovery of many de novo non-coding transcripts, it has few limitations. Firstly, non-
coding RNAs contain repeat elements which can nonspecifically bind to tiling probes, thus 
reducing confidence in sequence mapping. Secondly, microarray output lacks information 
on strand specificity, again impacting over all mapping of cDNA sequence. In an attempt 
to precisely identify non-coding RNAs and to distinguish them from the byproducts of the 
pervasive transcription, many groups have combined microarray data with human genome 
sequencing data as well as ChIP-seq data.   [113-115]. 
Next generation sequencing (NGS) 
Next generation sequencing provides in-depth understanding of the composition of 
human transcriptome by detecting low abundant transcripts. The deep sequencing of 
cDNA, also known as RNA sequencing (RNA-seq), has enable a comprehensive discovery 
of thousands of ncRNAs, expressed differentially in species, tissue and cell specific 
manner. The advancement in high through put sequencing technologies have enabled 
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sequencing of cDNA at greater depth and scale. It is with the advent of these approaches 
that uncovered identification of several non-coding transcripts encoded by the human 
genome. These approaches are sophisticated for mapping transcripts at nucleotide 
resolution. NGS coupled with sophisticated bioinformatic analysis can provide nucleotide 
resolution of mapped reads, alternative spliced isoforms and transcript abundance. RNA 
sequencing followed by mapping of sequences to a reference genome, enables  accurate 
computing of the abundance, density and splice-variants for each RNA [116] and enabling 
discovery of new exons.  In contrast to other sequencing techniques discussed above, RNA 
seq eliminates the use cDNA cloning and amplification steps, making it more streamlined. 
Interpretation of data for low expressing mRNAs further enhances its capability to detect 
lncRNAs as transcriptionally putative entities which were missed by conventional methods 
listed above. 
Furthermore, lncRNAs exhibit distinct chromatin marks as compared to protein 
coding mRNA. In addition to RNA transcriptional reads, chromatin signature K4-K36 at 
the promoter and H3K4me1 occupancy spanning the length of the non-coding transcript. 
 
1.5.3 Positional classification of lncRNAs 
LncRNA are transcribed from various locations within the genome. In order to 
better predict lncRNA functionality, genomic classification can provide insight into 
lncRNA mechanisms.  Most lncRNAs that have been discovered are named after their 
proximity to protein coding genes. Details of lncRNA classification with respect to their 
genomic location have been described below: 
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Long Intergenic lncRNAs (lincRNAs) 
LincRNAs, are the most abundant group of lncRNAs, are classified based on their 
genomic location and proximity to protein coding genes. Most lncRNAs are flanked by 
protein coding genes and are therefore termed as long intergenic non coding RNAs 
(lincRNAs). LincRNAs do not overlap with protein coding genes and can transcriptionally 
regulate expression of neighboring genes which is characteristic of enhancer like function 
[117]. LincRNAs were initially characterized by presence of K4-K36 histone occupancy 
at the promoters and across the transcriptional region in RNA pol II transcripts . 
 
Natural Antisense Transcripts (NATs) 
Non coding RNA that is generally transcribed from the complimentary strand of a 
protein coding or a non-coding gene is generally termed as NATs. Depending on its 
genomic loci with respect to protein coding genes, NATs can completely or partially 
overlap the complimentary protein coding genes. They can be classified into cis NATs or 
trans NATs. Cis-NATs are transcribed from the opposite strand and trans strand are 
transcribed elsewhere in the genome. NATs are mostly retained in the nucleus and can 
transcriptionally influence gene expression of paired genes. [118, 119]. 
 
Divergent lncRNAs 
Divergent lncRNAs are strategically localized antisense to protein coding genes to 
facilitate promoter region sharing. This bidirectional proximity to protein coding gene at 
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the transcription start site (TSS) enables co regulation of transcription and binding of 
transcription factors in a synergistic manner. Most divergent lncRNAs  act in cis to regulate 
the gene expression of neighboring genes mostly involved in development and 
transcriptional regulation. Divergent promoters are characterized by presence of large CpG 
islands and large first exons in the associated coding genes thus enabling transcription of 
both coding gene and associated lncRNA. Furthermore, bidirectional promoters giving rise 
to bidirectional transcripts show enrichment of H3K79me2 epigenetic marks and RNA pol 
II occupancy.  [120] 
 
Intronic lncRNAs 
Intronic lncRNAs are derived from the introns of annotated protein coding genes 
in a sense or antisense direction. lncRNAs are often co-transcribed with their protein 
coding genes and are poorly conserved across species. Evidence also suggests that intronic 
lncRNAs are further processed into small non-coding RNAs such as miRNAs and 
snoRNAs [121].  
 
Pseudogenes 
Pseudogenes are a class of non-coding transcripts that previously functioned to 
transcribe into a coding mRNA. However, during gene duplication events, pseudogenes 
lost their function to be translated into functional protein. Many studies suggest that 
pseudogenes ideally function as decoy RNAs to subvert gene expression as they share exact 




The number of non-coding RNA encoded by human genomes outnumbers the 
protein coding genes as evident by genome wide pervasive transcription. Non-coding 
regions of the genome that are actively transcribed, and are regulatory DNA elements also 
known as enhancers. Non-coding RNA transcribed from such regions are termed as 
enhancer RNA lnc-eRNAs. eRNA were identified by combining large scale transcriptome 
profiling with NGS like ChIP-seq however genome wide CAGE seq analysis failed to 
identify lnc-eRNA as they do not share the conventional characteristics of a mRNA at the 
5’ start site. Therefore, meta-analysis of H3K4me CHIP seq and deep seq revealed 
overlapping regions showing increased transcription in eRNA chromatin regions, thus 
termed as lnc-eRNAs. eRNAs exhibit robust transcription, and are capable of positively 
driving gene transcription however genome wide CAGE seq analysis failed to identify 
eRNA. These class of RNAs are characterized by exhibiting hyper sensitivity to DNAse 
treatment and have open chromatin structure facilitated by sparse nucleosome positioning. 
Furthermore, eRNAs have specific sequences to enable binding of transcription factors. In 
contrast to DNA enhancers, eRNA exhibit increased binding of transcriptional activators, 
increased chromatin accessibility to histone markers such as H3K27ac and CBP/p300 and 
are generally resistant to DNA methylation. Furthermore, openness in the chromatin 
structure additionally facilitates synergistic binding of transcription factors to drive gene 
expression. Although, eRNAs are a subcategory of lncRNAs, they differ is some features 
thus making the annotation for eRNA challenging. [123]. eRNAs are transcribed from 
enhancer like chromatin regions and are characterized by chromatin features like histone 
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H3 lysine 4 monomethylation (H3K4me1) In contrast to lncRNAs that are characterized 
by pol II occupancy and H3K4me3 marks. Furthermore, eRNAs are expressed at low levels 
and exhibit poor stability thus making their identification by conventional deep sequencing 





Circular RNAs are covalently joined circular RNAs that are produced as a result of 
non-canonical back splicing events. During splicing of non-coding transcripts, a 
downstream splice donor site is covalently linked to an upstream splice acceptors site, thus 
generating a circular RNA. Initially discovered as viroids circular RNA, discovery of 
cicrRNA in mammalian cells was considered as a non-functional product of splicing 
events. With increased resolution in RNA-sequencing and microscopic technologies, 
circRNAs were identified as function entities. In contrast to lncRNAs, circRNAs are 
generated as a result of alternative splicing events giving rise to a un polyadenylates and 
un-capped circRNAs, mostly localized in the cytoplasm. Similar to lncRNAs, circRNAs 




Figure 1.4 Positional classification of lncRNAs. Schematic showing the genomic 
locations for lncRNA transcription and their classification. Blue boxes represent protein 
coding genes and clear boxes with black outline represent lncRNA loci.  
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1.5.3 Coding Potential of lncRNAs 
By definition, lncRNAs are non-coding, however recent discoveries do account for 
presence of ORFs coding for small peptides within the lncRNA gene [112]. Moreover, lack 
of coding potential of lncRNAs can be attributed by: i. lack of sequence homology with 
known protein coding genes computed bioinformatically, ii. Lack of coding potential 
experimentally determined by polysome profiling and in-vitro translation assays and iii) 
poor conservation of putative ORFs encoded by lncRNA gene across species. However, it 
is imperative to determine the coding potential of a non-coding RNA and more importantly 
tease the function of encoding ORF from the functional lncRNA transcribed by the same 
gene [124].  
Polysome profiling of genes experimentally verifies cooccurrences of RNA with 
the ribosomes in the translational machinery, thus distinguishing coding versus non-coding 
RNAs. However, few studies have reported concurrence on ribosomes with RNA not 
coding for protein, thus compelling researchers to employ multiple approaches to conclude 
non-coding potential of an RNA. Such observations could also be contributed by 
translational noise due to non-specific binding or transient association as in case of 
screening for start site by the ribosome on the RNA.  
Codon substitution frequency (CSF) algorithm such as phyloCSF bioinformatically 
computes and scores each codon substitution in the input file by comparing it to conserved 
protein sequences. CSF is a highly sensitive tool that utilizes the power of conservation of 
protein coding ORFs across species to determine translational capacity [125]. Given that 
computational approaches such as CSF determines coding potential using conservation, it 
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may fail to account for small ORFS in non-coding genome as lncRNAs are not conserved 
and may encode for novel protein coding ORFs.  
  
1.6 Dissecting lncRNA-Protein functions 
lncRNAs are functionally versatile molecules that perform various functions. Many novel 
approaches have been developed in order to understand precise functioning of lncRNAs by 
evaluating RNA-protein, RNA-RNA and RNA-DNA interactions. Further, RNA centric 
approaches for evaluation of RNA association with a protein have strengths and limitation 




RNA Immunoprecipitation (RIP) 
 
Identification of RNA-protein interaction is fundamental to understanding lncRNA 
function. RNA immunoprecipitation (RIP) is an antibody based technique that allows 
identification of specific protein association with RNA of interest.  RIP can be performed 
in two different settings; Native and Crosslinked conditions. The Native method detects 
RNA-protein interactions in physiological conditions. However, during cell lysis native 
RNA-protein complexes can disassemble resulting in a poor lower experimental 
sensitivity. Chemical or UV crosslinking of cells can preserve the integrity of endogenous 
complexes, potentially providing a more comprehensive view of the RNA protein 
interactions within the cell. However, it is crucial to optimize cell type specific crosslinking 
reagents and duration to avoid non-specific crosslinking that may happen with RNA-
protein in close proximity than actual interaction.  For native RIP, cells are harvested and 
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lysed to be incubated with antibody raised against protein of interest coupled to magnetic 
beads or biotin. RNA protein complexes are pulled down followed by RNA purification 
and RNA quantification techniques. Cross-linked RIP starts by crosslinking cells followed 
by isolation of nuclear lysates and shearing of chromatin.  Using antibody raised against 
specific protein of interest, RNA is pulled to be analyzed leading to precise mapping of 
RNA bound to protein [126, 127].  
 
Cross-Linking and Immunoprecipitation (CLIP) 
 
The cross-linking and immunoprecipitation (CLIP) is a sensitive technique that 
captures association of closely linked RNA-protein interactions in a highly specific 
manner. Presence of highly abundant ribosomal proteins in cell lysates non-specifically 
bind to target RNA, thus failing to target legitimate interactions. CLIP is multi step 
protocol, which includes UV-irradiation to crosslink the complexes. The  optimization of 
each step based on cell type and protein of interest can provide functional insights by 
mapping RNA-protein interaction [128].  
 
Capture Hybridization Analysis of RNA Targets (CHART-MS) 
 
LncRNAs localized in the nucleus regulate gene expression in cis or trans by 
associating with specific chromatin sequence. Identification of chromatin region in 
association with lncRNA of interest can provide novel insights into mechanistic 
understanding of lncRNA biology. Capture hybridization analysis of RNA target 
(CHART-MS/seq) involves sequential capturing of lncRNA of interest using biotinylated 
antisense oligos in chemically crosslinked cells followed by high throughput identification 
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of protein by Mass spectrometry and/or DNA partners by next generation sequencing. To 
capture the lncRNA, single stranded DNA oligos, 20-28bp each in length, are designed and 
immobilized on streptavidin beads after RNA capture. Using RNAseH to proteolytic cleave 
RNA bound DNA followed by DNA purification and sample prep for deep sequencing. 
For protein read out, the captured RNA-Protein complexes are reverse crosslinked for 
protein elution and mass spectrometry analysis [129] . 
 
Chromatin Isolation by RNA Purification (ChIRP-MS/Seq) 
ChIRP is a novel RNA directed proteomic and genomic discovery technique that 
allows identification of lncRNA associated protein and genomic DNA complexes. Similar 
to CHART technique, ChIRP also utilizes crosslinking, RNA capture by ssDNA to capture 
lncRNA interaction with chromatin or protein complexes. In contrast to CHART, ChIRP 
uses 20mer antisense oligonucleotides with base pair overlaps. This increases the capture 
specificity to target RNA and reduces nonspecific capture. Cells are crosslinked using 
formaldehyde and subject to lysis to separate cytoplasmic extract and to release nuclear 
contents under temperature  controlled conditions. Chromatin are then sonicated to enable 
binding with biotinylated oligos followed by streptavidin mediated pull down. Protein or 
DNA is purified after reverse crosslinking of cells for Mass Spectrometric or next 





RNA Antisense Purification (RAP)  
RAP is a novel technique to map interactions of endogenous RNA in complex with 
the chromatin and proteins. Similar to CHART and ChIRP, RAP utilizes chemical 
crosslinking to fix endogenous lncRNA complexes with proteins and genomic DNA. It 
provides a genome wide view of lncRNA interaction with the chromatin by coupling it 
with high throughput sequencing or proteomics approach. Similar to CHART and ChIRP, 
RAP also involves biochemical purification of fixed lncRNA-protein or lncRNA-
chromatin endogenous complexes. One distinct feature that distinguishes RAP from 
CHART and ChIRP is the use of ultra-long (>120mer) overlapping probes that are tiled 
across the target sequence.  By the use of 120bp probes coupled with stringent 
hybridization and washing steps greatly reduces off target capture of RNA partners [131].  
 
Psoralen Analysis of RNA Interactions and Structures (PARIS) 
 
PARIS is a novel approach to resolve RNA-RNA interaction and RNA structure by 
combining in-vivo crosslinking, purification of RNA complexes and proximity ligation. 
PARIS employees the use of psoralen-derivative 4’-aminomethyltrioxsalen 
(AMT) that enables fixing of RNA helicases and alternative structure. AMT intercalates in 
RNA helicases at the sites of poly uridine, thus crosslinking the interacting strands. 
Following RNAse and protease treatment the crosslinked proximal strands are isolated and 
purified by 2D gel electrophoresis. Photo reversal and high throughput sequencing reveals 
alternative RNA structures and interactions between RNA in trans [85]. 
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Selective 2′-hydroxyl acylation by primer extension (SHAPE) 
SHAPE technique uses chemicals such as N-methylisatoic anhydride (NMIA) to elucidate 
higher-order structures of lncRNAs by taking advantage of flexible RNA backbone. During 
RNA conformation from linear to secondary structure, “flexible” nucleotides are subjected 
to nucleophilic reactivity towards electrophilic chemicals such as NMIA at the 2’hydroxyl 
group which can be mapped by a primer extension reaction. SHAPE is a highly sensitive 
technique that can map nucleotide flexibility at all 4 positions in a single reaction, 
differentiating between flexible and inflexible hydroxyl groups.  SHAPE gives a high 
resolution imprint of lncRNA secondary structure and binding partners [132].  
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1.7 Functions of lncRNAs 
 
 The identification of multitude of lncRNAs transcribed by human genome has 
unraveled novel mechanisms of gene regulation. In contrast to protein coding mRNA that 
are generally exported to the cytoplasm to be translated into proteins, , non-coding 
transcripts are observed to be localized asymmetrically in various compartments of the 
cells including mitochondria [133], extra cellular membranes [134], nucleus and exosomes 
[135]. Since lncRNAs have unique mode of mechanisms, the spatial localization is finely 
regulated to facilitate their association with functional complexes.  Moreover, sub-cellular 
localization can dictate the function of lncRNAs, contributing to effect on translation in 
cytoplasm and transcriptional regulation of genes in the nucleus. This section describes 
lncRNA function according to their distribution in the cell.  
 
Functions of cytoplasmic lncRNAs 
 Several studies have revealed expression of lncRNAs abundantly residing in the 
cytoplasm of cells [136]. LncRNAs found in the cytoplasm modulate functions pertaining 
to the cytoplasmic processes, predominantly affected the translation of mRNAs. 
Additionally, LncRNAs in cytoplasm can regulate mRNA stability and interfere with 
miRNA functions thus affecting mRNA turnover or modulating translation of specific 
mRNAs. Cytoplasmic lncRNAs employ several mechanisms to influence mRNA 




lncRNAs as Decoys  
Furthermore, LncRNAs act as “decoys” and associate with mRNA bound RNA 
binding proteins (RBPs). This interaction sequesters the RBPs from their target mRNAs 
thus dramatically decreases the occupancy of translating proteins on the mRNAs. Although 
lncRNAs are not translated into proteins, many studies show association of lncRNAs with 
the ribosomes [138].  This association of lncRNA to the ribosome subunit is rather 
confounding but some studies suggesting that may impact the mRNA translation. lncRNA 
Uchl1-AS1 is bound to the ribosomes and shuttles from the nucleus to cytoplasm in 
rapamycin stimulated conditions to bind to Uchl1 mRNA in the cytoplasm and promote its 
translation. Contrarily, AdipoQ-AS shuttles to the cytoplasm to form RNA duplexes with 
AdipoQ mRNA inhibiting its translation and modulating adipogenesis [139].     
LncRNAs as miRNA sponge 
Cytoplasmic lncRNAs interacting with miRNAs  dampen their function and are 
named as miRNA sponges, which affect the availability of miRNAs to bind with mRNAs.  
Cytoplasmic LncRNA-ATB is activated by transforming growth factor (TGF- β) to bind 
to miR-425-5p to facilitate TGF- βRII upregulation in hepatitis C infection resulting in 
progression of liver fibrosis [140]. miRNAs play important role in regulation of protein 
expression by binding to mRNA and initiating its degradation [141]. Interaction between 
lncRNAs and miRNAs are linked to several molecular functions in the cytosol. LncRNAs 
associate with miRNAs and prevent their binding to target mRNA thus inhibiting mRNA 
degradation and enabling protein expression [142]. Alternatively, lncRNAs can also 
compete with miRNAs by binding to their target mRNA and acting as miRNA sponge, 
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thus positively regulating gene expression. Such lncRNAs are known as competitive 
endogenous RNAs (ceRNAs) [143].  
Not only lncRNA binding to miRNAs to disrupt their functions, conversely certain 
miRNAs can target lncRNAs directly or indirectly to modulate their functions. lncRNAs 
targeted by miRNA are processed to be produced as siRNA or phased small interfering 
RNAs (phasiRNAs). PhasiRNAs are a special class of RNAs ranging in length from 21nt 
to 24nt that are derived from lncRNA locus, thus regulating gene expression[142]. It is 
now fairly understood that lncRNAs undergo alternative splicing more than protein coding 
mRNAs. This promotes generation of many miRNAs that are encoding within intronic 
regions of lncRNAs, thus acting as precursors of miRNAs [142]. 
 
lncRNAs modulating mRNA turnover 
Abundance of mRNA is directly proportional to protein expression in cytosol and 
are controlled by rate of transcription and rate of decay of mRNA. Cytosolic lncRNAs such 
as 1/2-sbsRNAs (half-staufen 1- binding site long noncoding RNAs) associate with mRNA 
in the cytosol and recruit Staufen1 for degradation thus activating mediated a Staufen-1 
mediated decay pathway (SMD) [144]. Contrarily, lincRNA-p21 associates with β-catenin 









LncRNAs in the nucleus 
  
LncRNAs are functional molecules that do not encode for any proteins. Several studies 
showing successful targeting of lncRNAs without perturbing the locus have further 
confirmed the role of lncRNAs as independent regulators of gene expression. As previously 
discussed, lncRNAs execute diverse functions owing to their differential expression in cell 
and tissues. Moreover, sub-cellular localization can also have a prominent impact on their 
role to execute diverse functions within a cell. To this note, this section will elaborate on 
lncRNAs and their functions in the nucleus. 
Nuclear localized lncRNAs can perform myriad of functions including interaction 
with chromatin modifying complexes, interactions with transcription modulation 
machinery, and also as regulators of post transcriptional functions, with transcriptional 
modulation of gene expression being the most prominent function. Within nucleus, 
lncRNAs exhibit diverse mechanisms to regulate gene expression that are discussed below.  
 
Interactions with chromatin modifying complexes 
Chromatin modifications are major drivers of changes in gene expression. This 
process is primarily prompted by epigenetic alteration of histones bound to the chromatin. 
Histone modifications, predominantly, methylation in addition to phosphorylation, 
acetylation and ubiquitination can alter gene expression. Chromatin residing lncRNAs 
associate with histone modulating enzymes promoting  histone modifications, thus 
influencing gene expression. Chromatin associated lncRNAs recruit histone 
methyltransferases and demethylases to promote histone modifications such as H3K4, 
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H3K36, and H3K79 to activate gene transcription and  H3K9, H3K27, and H4K20 for 
suppression of gene transcription.  
Alterations in chromatin complexes by lncRNAs results in modification of gene 
expression. LncRNAs are able to interact with chromatin modifying enzymes to implement 
temporary changes in genes expression by either repressing or activation transcriptional 
program. Mostly, chromatin modifying lncRNAs execute their function by i) acting as 
decoy, to sequester proteins away from their site of function; ii) as guides, to navigate 
chromatin modulation machinery to action site, and iii) as scaffolds, to facilitate association 
of proteins to the chromatin [146]. 
 
LncRNAs regulating histone methylation  
Polycomb groups (PcG) execute their function by associating with protein 
complexes specifically Polycomb repressive complexes (PRC1 and PRC2). PRC1 contains 
a RING1 E3 ligase domain and a chromobox (CBX), SUMO ligase activity domain [147]. 
The interaction of CBX domains with H3K9me and H3K27me enables its recruitment to 
repressed chromatin. Additionally, PRC2 complexes also contain H3K27 
methyltransferase, EZH1 and EZH2, that can modulate methylation activity of target genes 
[147]. LncRNAs associate with PRC2 or EZH1 complex to catalyze the generation of 
H3K27me3 repressive marks on the chromatin [147]. PRC1 and PRC2 lack DNA binding 
domain but interact with chromatin via protein and lncRNA tethers. In contrast to the PcG 
groups, Trithorax group (TrxG) contain a H3K4methyltransferase domain along with other 
activities such as H3K27 demethylase and acetyltransferase. TrxG also containing 
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chromatin modifiers and transcription factors to contribute to gene transcription [147]. 
Thus, lncRNAs can positively or negatively modulate gene expression by associating with 
PRC2 and TrxG groups. 
 LncRNAs regulating DNA methylation 
DNA methylation are important epigenetic modifications, catalyzed by various methylases 
mostly on the CpG islands of the promoters of the genes promoting transient silencing of 
the genes [148]. Several lncRNAs recruit DNA methyltransferases such as DNMT1 for 
maintenance, and DNMT3α/β for de novo to regulate gene expression[149] . lncRNA ATB 
is activated by TGFβ and suppresses p53 expression by associating and recruiting DNMT1 
to the locus. RIP mediated pull down of DNMT1 has revealed its association with several 
lncRNAs to influence gene expression by regulating DNA methylation. Several DNMT1 
associating lncRNA function in promoting oncogenesis, proliferation and migration of 
cancer cells [148].  
 
Transcriptional regulation by lncRNAs 
 Owing to the diverse mode of functions employed by lncRNAs, direct chromatin-
RNA interaction or association with the transcription factors also results in regulation of 
gene expression by lncRNAs. lncRNAs act as transcriptional cofactors, especially cis 
regulatory lncRNA that enhance the gene expression of neighboring genes by recruiting 
transcription factors. Additionally, lncRNAs can function as transcriptional interference to 
down regulate gene expression.  LncRNA Lethe and lncRNA Cox2 bind to heterogenous 
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nuclear riboproteins (hnRNPs) at the promoters of ISGs to suppress gene transcription thus 
acting like negative regulators of immune response .  LncRNAs also function as scaffolds 
allowing assembly of transcriptional units at the promoters of the genes for activating gene 
expression.  
1.8 LncRNAs involved in regulation of immune responses 
The cell and tissue specific expression of lncRNAs means that the exploration of their 
function is highly dependent on biological context. Immune cells such monocytes, 
macrophages and dendritic cells express pattern recognition receptors (PRRs) to recognize 
pathogen specific PAMPs and DAMPs. The ligand-receptor ligation subsequently activates 
several pathways including cellular differentiation, proliferation, transcriptional activation 
of ISGs, and suppression of immune events, all governed by specific protein players. RNA 
sequencing datasets on immune cells stimulated with immuno-stimulatory ligands have 
now confirmed involvement of lncRNAs in fine tuning of these signaling events in both 
innate and adaptive immunity. LncRNAs coordinate the activation of immune responses 
by various ways including interaction with chromatin, influencing transcriptional 
machinery, splicing for precise regulation of immune gene expression. This section 







1.8.1 lncRNAs in TLR signaling 
TLRs are the primary pathogen sensing receptors on immune cells. Several 
lncRNAs have been described to be key regulators in the immune response pathways. 
lncRNA THRIL was identified as a functional lncRNA, induced upon TLR2 stimulated 
THP-1 cells in a genome wide micro-array screen. lncRNA THRIL complexes with 
Heterogeneous Nuclear Ribonucleoprotein L (hnRNPL) for upregulation of TNF-α by 
associating with its promoter. Increased levels of TNFα in activated cells in turn suppress 
the expression of lncRNA THRIL to down regulate the pathway [150].  
The immune relevance of lncRNA Cox2 was first discovered and characterized in 
primary mouse BMDMs challenged with TLR2 ligand, Pam3CSK4. lncRNA Cox2, in 
association with hetero nuclear proteins, hnRNP-A/B and hnRNP A2/B1 was shown to 
transcriptionally inhibit a subset of pro inflammatory chemokines and ISGs such as CCl5  
however positively regulates IL6 expression [151].  Hu et al, demonstrated that lncRNA 
cox2 influences early and secondary gene program in LPS stimulated mouse macrophages. 
This impact on secondary genes such as IL6 was carried out by incorporation of lncRNA 
Cox2 in the ATP dependent switch/sucrose non fermentable (SWI/SNF) complex and 
subsequent chromatin remodeling of target genes [152]. lncRNA Cox2 homolog in human 
is located at the PTGS2 (COX2) locus described as lncRNA PACER. PACER is induced 
upon binding of CCCTC‐binding factor upstream of COX2. PACER sequesters NF-κB 
repressors to facilitate binding of p65/p50 subunit to COX2 genes to transcriptionally 
activate COX2 and ISGs [153].  
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TLR3 senses dsRNA in a Myd88 independent and exclusively via TRIF dependent 
pathway. LPS stimulation in breast cancer cells activates NF-κB  pathway simultaneously 
co-expressing NF-κB Interacting LncRNA (NKILA). LncRNA NKILA negatively 
regulates NF-κB  expression by binding to IκB/NF-κB  complex and obscuring 
phosphorylation sites and preventing IKK mediated phosphorylation, essential for NF-κB  
activation [154]. To assess the genome wide changes in lncRNA expression in TLR4 
signaling, Llott et al. performed RNA-seq on LPS treated primary human PBMCs. lncRNA 
eRNA-IL-1b and IL-1b-RBT46 were identified as the top most differentially upregulated 
lncRNAs in LPS stimulated PBMC. Given the close proximity to IL-1b gene, both 
lncRNAs positively coregulated the expression of IL-1B and CXCL8 specifically [155]. 
LncRNA EPS was initially identified as modulator of differentiation and apoptosis in 
erythroid cells. In immune cells, lncRNA EPS functions as a negative regulator of immune 
response by binding to hnRNPL to modulate gene transcription. In vivo and in vitro studies 
demonstrated increased chromatin accessibility to transcription factors at the promoters of 
ISGs in lncRNA EPS deficiency [156]. Several studies have suggested role of lncRNA 
MALAT1 in regulation of inflammatory responses. lncRNA MALAT1 acts as a negative 
regulator of NF-κB  dependent genes by associating with p65/p50 heterodimer and 
transcriptionally regulating NF-κB dependent gene program. lncRNA AS‐IL‐1α is an 
example of NAT, identified in listeria monocytogenes infected splenocytes. lncRNA AS‐
IL‐1α is encoded on the complementary strand of IL-1α genes and during NF-κB  activation 
of LPS challenge of BMDMs, transcriptionally regulate the expression of IL-1α gene [157]. 
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1.8.2 lncRNAs in host-virus interactions 
lncRNA NEAT1 was found to be upregulated upon Japanese encephalitis virus, 
IAV and HSV infection in mice. Additionally, lncRNA NEAT1 was shown to interfere 
with HIV replication by modulation nuclear to cytoplasmic translocation of HIV mRNA 
rev complex [158]. Cells treated with poly IC upregulated CXCL8 in a NEAT1 dependent 
manner. NEAT1 association with SFPQ, an inhibitor of CXCL8 gene transcription, 
resulted in its sequestration followed by increased  promoter accessibility and enhanced 
transcription of CXCL8 gene [159]. While majority of lncRNAs are located in intergenic 
regions of protein coding genes, Kambara et al. focused their study on lncRNA/protein 
pairs that were specifically induced in IFN-I stimulated primary human hepatocytes. 
LncRNA, BST2 IFN-stimulated positive regulator (BISPR) is transcribed from the 
bidirectional promoter shared with IFN stimulated gene BST2, which functions by 
restricting budding of enveloped virus from the cell surface. Upon viral infection, BST2 is 
induced in a BISPR dependent manner. BISPR restricts repressive activity of PRC2 
complex as well as complexes with EZH2 to facilitate BST2 expression for antiviral 
immunity [160].   Type I IFN responses are critical in anti-viral immunity. lncRNA-
CMPK2 alternatively known as lncRNA NRIR (Negative regulator of IFN Responses) is 
highly induced upon HCV infection in hepatocytes. lncRNA CMPK2 depletion results in 
increased induction of ISGs and reduced replication of HCV along with its nuclear 
localization is suggestive of its transcription role in regulation of ISGs [161]. While most 
lncRNAs in viral infections are positive regulators of anti-viral immune response, lncRNA 
NRAV (Negative regulator of Antiviral Response) is downregulated during influenza 
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infection in human alveolar epithelium cell line A549. Molecular mechanism of lncRNA 
NRAV revealed its association with the promoters of IFITM3 and MxA to suppress their 
transcription during IAV infection. Both in vitro and transgenic mouse studies revealed its 
role in promoting IAV replication and therefore a negative regulator of IFN-I response 
[162]. Similar to lncRNA NRAV, lncRNA LUARIS (lncRNA up-regulator of antiviral 
response IFN signaling) was also downregulated in encephalomyocarditis virus (EMCV) 
infections. It is an IRF3 dependent lncRNA that is associated with hnRNPU during HBV 
or HCV infection to activate expression of various ISGs. Downregulation of lncRNA 
LUARIS causes decreased ISG levels and a failure in clearance of virus [162]. lncRNAs 
not only impact innate immune response to viral infections but also play role in virus 
induced adaptive immunity. One such example is of lncRNA NRON that sequesters NFAT 
family of proteins in the cytoplasm to restrict transcription in human CD4+ T cells and 
Jurkat cells. In the event of calcium signaling, NFAT proteins are dephosphorylated and 
translocated to the nucleus to transcribe HIV-I transcription and replication. Therefore, 
lncRNA NRON acts a negative regulator of HIV-1 progression by inhibiting NFAT1 
activity and restraining it in the cytoplasm [163]. Majority of lncRNAs studies to have role 
in immune regulation either belong to lincRNAs or NATs, however lncRNA Lethe is an 
example of pseudogene regulating immune response. As described in previous sections, 
pseudogenes are protein coding genes that have lost their function to produce a functional 
protein due to gene duplication event. In a TNFα screen in Mouse Embryonic Fibroblasts 
(MEFs), LETHE was identified as a top scoring pseudogene lncRNA. Nuclear localized 
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LETHE, binds to NF-κB  subunit RelA, sequestering it from chromatin and thus negatively 
regulating NF-κB  gene signature [164]. 
 
1.8.3 Pathogen derived lncRNAs 
The coexistence of host and pathogen requires a process of continuous evolution of 
immune system for survival, protection and proliferation of both. During immune-
evolution, as the host expands its repertoire of genes for pathogen detection and clearance, 
viruses also attain novel approaches to circumvent host surveillance. Long non coding 
RNAs are an emerging class of novel regulators in host for fine tuning host-pathogen 
interactions. Similarly, it is not surprising to discover that many viruses also encode for 
lncRNAs by their genome for attaining enhanced infectivity and circumventing host 
machinery. The genome of most viruses is very compact and restricted for encoding for 
essential genes. Therefore, it is believed that like most protein genes are essential for 
pathogenesis, lncRNAs encoded by viruses are also essential for their functions.  
The most well characterized example of viral encoded lncRNAs is of VA RNA, (Virus-
associated RNA) 160bp in length, transcribed by RNA polymerase III in adenoviruses 
[165, 166]. VA-RNA is detected at a high copy number (10^8 copies/cell) in infected cells 
and functions by inhibiting the activity of PKR by competitively associating and inhibiting 
binding of dsRNA, a byproduct from viral replication.  Activated PKR phosphorylates 
translation elongation factor eIF2, to suppress protein translation in virus infected cells. 
VA-RNA acts as a decoy and binds to PKR to inhibit phosphorylation of eIF2, and to 
activate protein translation to support viral replication and progression [167, 168].    
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Oncogenic herpesvirus, Epstein-Barr virus (EBV) encodes two abundant non-coding 
RNAs, EBV-encoded RNA 1 (EBER1) and EBER2 [169]. Similar to VA-RNA, EBER 
RNA is also a product of RNA polymerase III, is expressed at a high copy number in 
infected cells as well as binds to PKR to prevent inactivation of  viral protein translation 
and is recognized by cellular autoantigen LA, a ribosomal RNA chaperone that recognizes 
the 3’ ends of  RNA pol III transcripts. EBER1 association with LA also stimulates TLR3 
pathway when released extracellularly via secretory vesicles such as exosomes [170, 171]. 
Additionally, EBER1 also associates with AU-rich element-binding factor 1 
AUF1/heterogeneous nuclear ribonucleoprotein D (hnRNPD) and ribosomal L22 protein 
for interfering in stabilizing AU rich elements and impacting L22 localization to 
nucleoplasm respectively. Nuclear localized EBER2 RNA binds to transcription factor 
PAX5 at the terminal repeat sites of EBV genome to regulate gene expression of latent 
genes [172]. 
The Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes a 1.1Kb polyadenylated 
nuclear (PAN) RNA, expressed at 500,000 copies per cell and is essential for virion 
production during lytic cycle[173]. The PAN RNA consists of a 5’ ORF57 binding site and 
a 3’ triple-helical stabilization element (ENE) proceeding the poly A tail and syntenically 
conserved in three other γ-herpesviruses (rhesus rhadinovirus [RRV], equine herpesvirus 
2 [EHV2], and retroperitoneal fibromatosis-associated herpesvirus Macaca nemestrina 
[RFHVMn]) [172-175]. Various studies using oligonucleotide depletion of PAN RNA 
suggested decreased viral mRNA and reduced capacity to produce viral particles [174, 176, 
177]. Global high-throughput assessment of PAN RNA interactions using ChIRP in KSHV 
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infected B cells revealed  PAN RNA association with the latency-associated nuclear 
antigen (LANA) protein to inhibit LANA’s interaction with H3 chromatin.[174]. Human 
cell infected with herpesvirus HCMV shows highly abundant viral non coding RNA β2.7 
that function to prevent mitophagy and enable sustained ATP production for viral 
progression.  
 Interestingly, β-herpesviruses HCMV infection in human cells result in high 
expression of a 2.7kb lncRNA ( β2.7) contributing to viral life cycle [178]. lncRNA β2.7 
is highly abundant in infected cells and prevents mitophagy in host cells enabling steady 
ATP production, essential for viral replication [178]. Additionally, human γ-herpesvirus, 
EBV also expresses a nuclear 2.4kb RNA transcribed from early BHLF1 gene regulating 
viral DNA replication [179]. 
 The transcription of lncRNAs by pathogens including viral encoding lncRNAs 
provide substantial evidence for lncRNA mediated regulation of biological processes 
across multiple organisms. Additionally, several studies have now described virus 
mediated hijacking of immune pathways in human cells to enhancing infectivity and 
enabling their propagation in the host. It is now evident that virus expressed lncRNAs also 
play crucial role in mediating subverting immune responses in human cells. Therefore, 
further discoveries and characterization of lncRNAs expressed by pathogen will enhance 
our understanding of initiation and propagation of infections and open new avenues for 






1.9  Therapeutic Targeting of lncRNAs for Disease Intervention 
 
 
Dysfunction of immune system is implicated in a myriad of heterogenous disorders. 
Autoimmune disorders such as psoriatic arthritis, coeliac disease, rheumatoid arthritis, 
psoriasis,  type 1 diabetes (T1D), autoimmune thyroid disease (AITD) and inflammatory 
bowel diseases (IBDs) are characterized by different symptoms, however the underlying 
dysfunction in immune pathways are commonly shared. These findings are not just limited 
to sterile immune disorders, but also span across pathogenic infections where 
susceptibility, duration, intensity of immune response and recovery are linked to genetic 
and environmental factors [180]. 
Advances in immunochip assays,  for fine mapping of immune gene loci to achieve 
single nucleotide resolution have enabled identification of several single nucleotide 
polymorphisms (SNP) at the disease specific genetic loci such as HLA, TNF-α pathway, 
IL17 pathway, playing overlapping roles in various disorders. Additionally, lncRNA 
profiling of disease associated genomic regions showed enhanced lncRNAs association to 
those regions[181]. Furthermore, such studies coupled with GWAS, allowed a 
comprehensive mapping of SNPs in disease susceptible loci, and a majority of SNPs were 
identified in non-coding regions of the genome [182]. The majority of disease associated 
SNPs are located in lncRNA transcribing regions of the genome and can influence lncRNA 
expression, secondary structure and expression {Castellanos-Rubio, 2019 #193. Given the 
emerging role of lncRNAs in biological processes and immune disorders, therefore 
understanding of lncRNAs associated SNPs in disease pathologies can unravel novel 
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therapeutic interventions [181]. However, the molecular mechanism of how these variants 
change lncRNA function in disease pathology remains largely unexplored. 
 
Celiac disease is an immune mediated disease characterized by intolerance to 
undigested gluten from wheat, rye and barley. About 40% of cases are developed in 
population with genetic susceptibility mapping to human leukocyte antigen (HLA) and 
only 3% of those are in the protein coding exonic region of the gene [183]. Many lncRNAs 
have been identified through differential expression analysis of lncRNAs from samples 
from celiac disease patients and healthy controls. MHC genotyping of samples from celiac 
disease patients have unraveled lncRNA-HCG14 showing significant correlation with 
disease score. lncRNA HCG14 is enriched in an HLA independent manner and regulates 
NOD1 mediated immune response in genetically susceptible patients [184].  Although, 
many lncRNAs have been associated with celiac disease, only the role of lncRNA13 has 
been thoroughly characterized molecular role in celiac disease. lncRNA13 contains a celiac 
disease associated haplotype block, SNP rs917997 and lies antisense of IL18RAP gene. In 
resting cells lnc13 associates with hnRNPD to represses pro-inflammatory gene expression 
[181].  In stimulated conditions, lncRNA13 is repressed to allow expression of 
proinflammatory genes. Under stimulated conditions, lnc13 is degraded by decapping 
enzyme 2 (DCP2) The hyper activation of inflammatory gene signature is attributed by low 
expression of lncRNA 13 in celiac disease intestinal cells contributing to inflammation and 
disease pathogenesis. The lnc13 gene locus harbors a total of 6 SNPs associated disruption 
in gene signature, and nucleotide changes result in binding affinity of lnc13 to hnRNPD, 
thus increasing inflammatory gene program [185].  
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Atherosclerosis is an inflammatory disease of arterial wall prompted by chronic 
inflammation, lipid disbalance and metabolic dysregulation. Inflammatory cytokines 
released by circulating monocytes further exacerbate the disease, thus confirming role of 
PBMC contributing to the pathogenesis of the disease. GWAS studies revealed presence 
of SNP rs28507118 within the intronic region of lncRNA LINC00305, which is highly 
expressed in atherosclerosis plaques and PBMCs. LINC00305 interacts with lipocalin-1 
interacting membrane receptor (LIMR) to increase interaction with aryl-hydrocarbon 
receptor repressor (AHRR) for NF-κB activation and induction of proinflammatory gene 
expression. LINC00305 altered inflammatory gene signature in monocytes, which 
influenced caused phenotypic changes in vascular smooth muscle cells to induce formation 
of plaques [186]. Furthermore, LINC00305 also interacts with miR-136, which is known 
to have role in apoptosis mediated atherosclerosis [187]. 
 Inflammatory bowel diseases such as ulcerative colitis and celiac diseases are 
primarily driven by inappropriate inflammatory responses against gut microbiota. Meta-
analysis of several GWAS data have suggested IBD susceptible loci that mostly encompass 
lncRNA genes. Amongst the several lncRNAs implicated to harbor IBD susceptible SNPs, 
lncRNA NeST was found to be localized to such genomic region and was also differentially 
regulated in IBD patients. IBD associated SNP, SNP rs7134599 is located within the 







1.9.1 LncRNAs as therapeutic targets 
 
Nucleic acid based therapeutics approaches are a novel strategy towards drug 
discovery. LncRNAs represent a significant population of non-coding genome and 
expression of several lncRNAs are upregulated or downregulated in infection, 
inflammatory and auto-immune disorders. Additionally, many inflammatory disorders are 
associated with SNPs that do not overlap with protein coding genes, but lie in the non-
coding regions of the genome. Therefore, lncRNAs provide a promising new opportunity 
to be therapeutic targets for infectious diseases and auto-immune disorders. LncRNAs as 
therapeutic targets have several advantages over protein coding genes making them great 
candidates for drug targets. Firstly, lncRNAs perform defined functions in specific cells 
and tissues. This feature enables specific targeting in tissue of interest without aberrant off-
targets effects.  Protein coding genes on the other hand are uniformly expressed through 
out various cells and tissues, and are often encountered by non-specific targeting.  
Secondly, lncRNAs can fine tune host pathogen interaction using diverse mode of actions. 
This creates a number of strategic approaches for therapeutically targeting lncRNAs 
implicated in diseases. LncRNAs can be targeted post transcriptionally using RNAi and 
ASO approaches as discussed in section 1.9 (Targeting of lncRNAs for Disease 
Intervention ). Further, the inhibition of lncRNA transcription by blocking promoter 
regions or directing transcriptional machinery away from lncRNA locus may also be used 
as an indirect mode of targeting the lncRNAs. Finally, lncRNA functions can be targeted 
by perturbing their interactions with protein complexes. These approaches facilitate 
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targeting lncRNA functions using diverse methodologies thus reducing constraints and 
expanding flexibility for therapeutic targeting of lncRNAs.  
1.9.2 Post transcriptional targeting of lncRNAs 
 
Given that RNA-RNA and RNA-DNA hybrids can be targeted for enzymatic cleavage and 
degradation by RNAi or ASOs introduces new opportunities for drug intervention in 
lncRNA field. Such approaches enable targeting of inaccessible nucleic acid complexes 
with ease. Stein et al discusses the successful implementation of various oligo based 
approaches for various diseases approved by Food and Drug Administration (FDA) [188]. 
Vitravene, also known as Fomivirsen  is an ASO based therapeutic, first of its class 
approved for cytomegalovirus (CMV) retinitis. The 21mer complementary ASO binds to 
CMV immediate-early (IE)-2 protein, which is required for viral replication. Similarly, 
various modifications of ASOs and their corresponding drugs Macugen for macular 
degeneration, Kynamro for hypercholesterolemia, Eteplirsen for Duchenne muscular 
dystrophy are some of the examples of FDA approved successful ASO drugs currently 
administered to patients [188].  
 
1.9.3 Targeting of lncRNAs for Disease Intervention 
 
It is now established that lncRNAs have regulatory role in fine tuning to gene expression 
in various biological processes. Now that the field of lncRNAs have advanced for better 
cataloging of lncRNAs, understanding of molecular mechanism of action is very limited. 
The first step for functionally characterizing lncRNA, is to understand their contribution to 
biological phenotype. In order to generate lncRNA knock down or knock out cells, a 
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number of methods have been utilized, with some of the technologies showing promise in 




RNAi pathways were first discovered in Caenorhabditis elegans, demonstrating 
knock down of specific genes using dsRNA molecules [189, 190] RNAi is a commonly 
used technique for gene knock down studies and utilizes RNAi induced silencing complex 
(RISC) for gene suppression. The RISC loading complex is a trimeric protein complex 
consisting of Dicer, TAR RNA binding protein (TRBP), Ago2 proteins that process long 
dsRNA into short RNAi molecules to be loaded to Ago2 protein for degradation of target 
mRNA. RNAi functions in cytoplasm, specifically in the endoplasmic reticulum at the site 
of protein translation of mRNAs [191].  Following the discovery of RNAi mediated gene 
targeting, several pharmaceutical companies employed RNAi based therapies for 
successful use in drug discovery. Double stranded RNA are susceptible to endogenous 
nuclease mediated degradation, therefore RNAi modifications such as 20-O methyl(20-O-
Me) sugar residues and phosphorothioate linkages in the 3’ end as well as improvements 
in mode of delivery enhances their stability, druggability and bioavailability [192].   
 
Anti-sense Oligos (ASOs) 
First generation Antisense Oligos or ASOs are synthetically synthesized single 
stranded nucleotide sequences, typically 12-20bp in length, that bind to  complementary 
lncRNA sequence through Watson-Crick base pairing [193, 194]. ASO’s recruit RNAse 
H, which are predominantly present in the nucleus, to degrade the complimentary lncRNA 
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sequence, thus enabling efficient targeting of nuclear localized lncRNAs. Additionally, 
ASO can target lncRNAs specifically blocking their splicing, polyadenylation and 
localization thus suppressing their expression and reducing accumulation. Unlike siRNAs, 
ASOs are single stranded and low molecular weight 5000-8000Da allowing an efficient 
RNA targeting and potential therapeutic molecule [195].  
Second generation ASOs contain 8-10bps of phosphorothioate DNA nucleotides that are 
encompassed by modified nucleotides called as “gapmer”.  Introduction of gapmer in the 
backbone makes ASOs resistant to nucleases mediated degradation. In order to optimize 
the efficiency of ASO’s , several other modifications have been incorporated including a 
2′-O-methoxyethyl (MOE) modification of the sugar backbone for better stability and 
reducing non-specific interactions [195].  However, this approach greatly reduced their 
RNAse H activity rendering them unsuitable for cleavage mediated mRNA targeting. 
Uniformly modified ASOs contain modification in all the sugar in the backbone, although 
unsuitable for cleavage reactions, these molecules can alter splicing events of target RNAs. 
Spinraza, is one the first FDA approved splice switching drug for treatment of spinal 
muscular dystrophy. Another novel modification involves incorporation of 2’,4’-constraint 
(cET modification) in the residues adjacent to the deoxy central region making them 
smaller with enhanced efficiency. As with every technique, ASOs also have challenges 
especially when target RNA has secondary structure, or rapid turnover that inhibits optimal 
binding and downregulation of gene expression. ASOs are a promising class of druggable 
targets, computationally designed to reduce off-target effects and increased potency [195].  
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Morpholinos  
Morpholinos are uncharged analogs of nucleic acids, 25 subunits of 4 nucleotides 
assembled to form a structure. Morpholinos complimentary to target mRNA can modulate 
post transcriptional modification including splicing, capping and translation as well as 
inhibit the interaction of mRNA with protein molecules. Morpholinos have been 
successfully used to manipulate gene expression in zebrafish and Xenopus sp. In a RNAse 
H and RISC complex independent mechanism [196]. Morpholinos can also be modified by 
replacing sugar groups with methyl- enemorpholine rings. Exondys51TM is one of the first 
morpholino drug approved for treatment of Duchenne muscular dystrophy by targeting 
dystrophin mRNA splicing. Although studies targeting lncRNA by morpholinos are 
limited, yet it provides a compelling gene targeting strategy for lncRNAs [197].  
CRISPR/cas9 approaches for targeting lncRNAs 
With the advances in genome editing techniques, CRSPR/cas9 mediated targeting 
of lncRNA is at its forefront. CRISPR/cas9 utilizes the use of bacterial endonuclease 
enzyme, cas9 to target genome in a sequence specific manner guided by a single-guide 
RNA (sgRNA). Once cas9-sgRNA complex is directed towards the sequence of interest, 
cas9 creates dsDNA breaks in the genome which are then repaired by the non-homologous 
end joining thus creating indels and mismatch mutations.  Unlike mRNA, where use of 
single guide can introduce frame shift insertions/deletions to prevent translation of any 
functional protein product, lncRNA targeting by CRISPR-cas9 require synergistic cleavage 
by two sgRNA for partial and complete excision of lncRNA gene. Some lncRNAs such as 
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eRNAs and bidirectional RNAs also exert their function through act of transcription, 
therefore excision of promoter region and annotated transcription start is a more efficient 
strategy for targeting lncRNA. Recently, amalgamation of CRISPR and RNAi techniques 
introduced CRISPRi involving recruitment of an enzymatically inactive dcas9 and sgRNA 
to the gene of interest for transcriptional downregulation of target genes. Additionally, 
identification of CRISPR-Cas13 system enables degradation of RNA targets. 
Targeting lncRNAs by small molecules 
It is now fairly understood that most of the lncRNAs secondary and tertiary 
structure is fundamental to their function. Disruption of lncRNA folding can result in loss 
of their function. Several techniques as detailed in section 1.6 summarizes techniques for 
mapping lncRNA structure important for their biological function. This important feature 
of lncRNA can be exploited for discovery of inhibitory molecules that would hinder 
formation of secondary structures. For example, small molecule targeting of viral and 
bacterial riboswitches, that play essential role in gene expression, is potential avenue for 
mRNA based targeting of infectious diseases [198]. Genetic disorders such as Huntington’s 
Disease, fragile X syndrome and myotonic dystrophy are caused primarily because of 
lncRNA secondary structure driven disruption in gene expression. Similarly, formation of 
secondary structures of lncRNA NEAT1 and MALAT1 contribute to their function. Such 
mechanisms of actions which are driven by lncRNA secondary structures can be potentially 
targeted by small molecules making them promising candidates for therapeutics targeting 
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Long non-coding RNAs (lncRNAs) are important regulators of biological 
processes including immune responses. The immunoregulatory functions of lncRNAs have 
been revealed primarily in murine  models with limited understanding of lncRNAs in 
human immune response. Here, we identified  lncRNA LUCAT1 significantly regulated in 
human myeloid cells stimulated with lipopolysaccharide (LPS) and other activators of the 
innate immune response.  Targeted deletion of LUCAT1 in primary human DCs and 
monocytic cell lines revealed an increased expression of type I interferon stimulated genes 
(ISGs) in response to LPS.  In contrast, CRISPR-activation to increase LUCAT1 
expression resulted in a reduction of the inducible ISG response. LUCAT1 is induced and 
retained in the nucleus where it is associated with the chromatin. Additionally, the promoter 
region of IFN- and ISGs showed enrichment of RNA polymerase II and increased 
H3K4me3 in cells lacking LUCAT1, suggesting LUCAT1 limits transcription of these 
target genes. Unbiased discovery of RNA binding proteins identified STAT1 interaction 
with LUCAT1 in the nucleus. Together, our study highlights a novel anti-inflammatory 
role of lncRNA LUCAT1, as a post-induction feedback regulator to restrain the immune 
response in human cells.   
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Introduction 
Type-I Interferon (IFN-α/β) production and signaling is instrumental for effective 
anti-viral immunity. The type I IFN response is initiated upon recognition of pathogen-
associated molecular patterns (PAMPs) such as viral nucleic acids or lipopolysaccharide 
(LPS). The main transcription factors that induce the production of IFN-α/β are the 
interferon regulatory factor 3 (IRF3) and IRF7. Interferons themselves are potent cytokines 
that induce the expression of hundreds of interferon-stimulated genes (ISGs) in an auto- 
and paracrine manner through binding to the heterodimeric interferon receptor (IFNAR). 
ISGs interfere with viral replication and support pathogen clearance  [199]. The activation 
of IFN-α/β signaling is tightly regulated through the JAK-STAT1 signaling pathway and 
dysregulation of this signaling pathway can lead to persistent inflammation and 
autoimmune diseases such as lupus [48, 200, 201]. While the importance of numerous 
protein players in these pathways has been well elucidated, the role of non-coding RNAs 
(ncRNAs) in the regulation of the IFN response is less well understood. Amongst the 
various classes of ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs 
(lncRNAs) are the most widely studied in biological processes including host pathogen 
interactions [146, 202]. 
With over 17,000 lncRNAs encoded by the human genome, this group constitutes 
the largest class of ncRNAs and represents a large portion of human genes (Gencode 
v32,[203] [204]). Arbitrarily described as greater than 200 bp in length and lacking protein-
coding capacity, lncRNAs have been shown to modulate transcription, translation and post-
transcriptional processing of mRNAs in a species- and tissue-specific manner [205, 206]. 
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lncRNAs can either act in cis to alter the expression of neighboring genes or act in trans 
and execute various functions throughout the cell. These ncRNAs can exhibit diverse roles 
in cellular and developmental processes but also in diseases such as cancer [207-209], 
autoimmunity [185] and cardiovascular  disease [210, 211]. A limited number of lncRNAs 
have been discovered and characterized as immune regulators including lncRNA-COX2 
[151], THRIL[150], lncRNA-EPS[156], and Morrbid [212, 213]. The molecular 
mechanisms that underlie the immunoregulatory functions for these RNAs are diverse. For 
example, lncRNA-COX2 and THRIL are nuclear lncRNAs that form complexes with 
heterogenous nuclear ribonucleoproteins (hnRNPs) to alter the expression of target genes 
[151, 156], whereas Neat1 translocate to the cytoplasm to promote inflammasome 
assembly and stabilize Caspase-1, an inflammatory caspase that controls the proteolytic 
maturation of interleukin-1 beta (IL-1β) and related cytokines [214]. lncRNAs are poorly 
conserved between humans and mice, with most of the studies that have been conducted to 
date being in murine models. Thus, very little is known about how lncRNAs influence 
immune responses in human cells. 
In this study, we utilize high throughput RNA sequencing on LPS stimulated or 
virus infected human dendritic cells (DCs) and identified LUCAT1 as one of the strongest 
induced lncRNA. LUCAT1 was first identified as Smoke and Cancer Associated lncRNA-
1 (SCAL1) in lung cancer cells [215]. LUCAT1/SCAL1 is induced upon exposure of 
human lung cell lines to cigarette smoke in a KEAP1-NRF2-dependent manner and shown 
to protect cells from oxidative stress [215]. Since this initial discovery, LUCAT1 has been 
associated with various forms of cancer and plays a pivotal role in tumorigenesis by 
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promoting cell migration [216], cell proliferation [217], and metastasis [216, 218-220]. 
Furthermore, LUCAT1 was shown to be highly upregulated in retinal muller glial cells 
upon Toxoplasma gondii infection indicating a potential role in host-pathogen interactions 
[221].  
Here, we describe lncRNA LUCAT1 as a dynamically regulated gene which 
functions as a potent regulator of the IFN-I response. Genetic ablation of LUCAT1 using 
virus-like particles loaded with Cas9 and sgRNA, so-called Nanoblades, resulted in 
hyperactivation of ISGs and pro-inflammatory cytokines in the human monocytic cell line 
THP-1 as well as in primary human DCs following LPS stimulation. Accordingly, 
overexpression of LUCAT1 in THP-1 cells using CRISPR activation (CRISPRa) 
attenuated the inducible IFN-α/β response. We found that LUCAT1 interacted with STAT1 
in the nucleus and in so doing restrains ISG expression. The induction of LUCAT1 is 
therefore a post-induction feedback regulatory mechanism to limit the magnitude and 
duration of the IFN-I response.   
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Results 
LUCAT1 is an inducible lncRNA upregulated in activated primary human cells upon 
immune stimulation 
To assess lncRNA expression, we performed RNA sequencing in primary human 
monocyte-derived dendritic cells (hMDDC) stimulated with LPS, herpes simplex virus 1 
(HSV-1) and influenza A virus (IAV) for 2 and 6 hours (Figure 2.1). RNA sequencing data 
from these cells revealed differential expression of several non-coding transcripts many of 
which were induced in a ligand specific manner (Figure 2.2a). Among these lncRNAs was 
a previously described lncRNA, LUCAT1 [215], which showed significant increase in 
expression after stimulation with all three ligands (Figure 2.2b). LUCAT1 reaches the 
maximum induction as early reaching maximal expression 2 hours post LPS stimulation 
(Figure 2.2c).  
We also employed RT-qPCR to validate these findings, which showed rapid and 
significant  LPS induced expression of LUCAT1 at 2 hours in primary human CD14+ 
monocytes, DCs and macrophages upon LPS stimulation (Figure 2.3a-c). RT-qPCR 
analysis of LUCAT1 expression also showed significant induction with IAV and HSV-1 
in a time-dependent manner in hMDDC (Figure 2.3d). Additionally, the human monocytic 
cell lines THP-1 as well as BLaER1 cells, which can be transdifferentiated into a 
monocyte-like phenotype [222], also displayed significant enrichment of LUCAT1 in a 





Figure 2.1 Workflow for identification of human specific lncRNAs  
Schematic showing sample preparation for RNA sequencing in human DCs. Peripheral 
blood from 2-3 donors was subjected to density gradient centrifugation for separation of 
white blood cells and platelets present in the buffy coat. CD14+ monocytes were separated 
using magnetic beads and differentiated into dendritic cells using a cocktail of hIL4 and 
hGMCSF for 6-7days. Post differentiation, cells were stimulated with LPS, HSV-1 and 
IAV-PR8 for 2hr and 6hr followed by RNA isolation and library preparation.  
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Figure 2.2 Analysis of RNA-seq data in human Dendritic Cells.  
Venn diagram showing number of differentially upregulated lncRNAs in LPS, HSV-1 and 
IAV treated hDCs (log 2 TPM>2).  b Heatmap of lncRNAs differentially expressed non-
coding RNA (log 2 TPM>2 fold over NT, Q value < 2) following LPS, HSV-1, IAV 
treatment at 2hr and 6hr in hDCs. c LUCAT1 expression from RNA sequencing 
represented in TPM values for LPS, HSV-1 and IAV stimulated hDCs at 2hr and 6hr time 
points (N=2, one-way ANOVA Dunnett’s multiple comparisons test) . Data is represented 
as ± SEM * P ≤ 0.05, ** P ≤ 0.01) 



























Figure 2.3 : LUCAT1 is an inducible lncRNA upregulated in activated primary 
human cells upon immune stimulation 
a RT-qPCR analysis of LUCAT1 expression in human DCs(Left)(n=4 donors); one-way 
ANOVA Dunnett’s multiple comparisons test), b.CD14+ monocytes (middle)(n=3 donors; 
unpaired t-test) and c. human macrophages (Right) upon LPS stimulation(n=2 donors; one-
way ANOVA Dunnett’s multiple comparisons test). d. RT-qPCR analysis of LUCAT1 
expression in hDCs stimulated with IAV and HSV-1 for 2hr, 6hr and 24hr time points (n=4, 
one-way ANOVA Dunnett’s multiple comparisons test). Data is represented as ± SEM ** 






































































Figure 2.4 : LUCAT1 is an inducible lncRNA upregulated in human monocytic cell 
lines. 
a. RT-qPCR analysis of LUCAT1 expression in THP-1 cells stimulated with Pam3, LPS, 
R848 and HSV-1 for 2hr, 6hr and 12hr time points (n=4, one-way ANOVA Dunnett’s 
multiple comparisons test, LPS). b. RT-qPCR analysis of LUCAT1 expression in BlaER1 
cells stimulated with LPS from 30min to O/N time points (n=3, one-way ANOVA 
Dunnett’s multiple comparisons test). Data is represented as ± SEM ** P ≤ 0.01, *** P ≤ 




























































































































qRT-qPCR measures levels of RNA transcripts in cells which could result from 
RNA transcription or alterations in the stability of RNAs [223]. We wanted to understand 
the kinetics of LUCAT1 expression further and employed metabolic pulse-chase labelling 
of RNA using 4-thiouridine (4sU) in LPS-stimulated hMDDCs, followed by qPCR using 
exon-spanning primers. By comparing labelled RNA to total RNA, we validated the 
kinetics of LUCAT1 induction. We observed that the mature LUCAT1 RNA was newly 
transcribed maximally by 2 hours, consistent with the RT-qPCR analysis. The kinetics of 
IFN-β mRNA overlapped that of LUCAT1 (Figure 2.5a). As expected, we did not observe 
changes in the expression of the RNA for the housekeeping gene GAPDH (Figure 2.5a). 
Absolute quantification of LUCAT1 RNA revealed that LUCAT1 is expressed at low copy 
numbers in resting cells but upregulated to ~ 50 copies per cell upon LPS stimulation after 





Figure 2.5 Pulse chase labeling of actively transcribed RNA and determination of 
absolute copy number. a. 4SU incorporation in LUCAT1, IFNβ and GAPDH mRNA in 
LPS stimulated hDCs. b. RT-qPCR analysis for absolute copy number of LUCAT1 in LPS 
stimulated hDCs (n=3 donors; one-way ANOVA Dunnett’s multiple comparisons test). 





In contrast to protein coding genes, lncRNAs are expressed at lower abundance and 
therefore have poorly annotated transcription start and end sites [203]. To identify the 5’ 
and 3’ sequence ends of LUCAT1 transcripts, we performed Rapid Amplification of cDNA 
Ends (RACE) from LPS-stimulated hMDDCs. Through sequencing of the RACE products, 
we could identify isoforms with the predicted 5’ ends from the two LUCAT1 isoforms 
(NR_103548.1 and NR_103549.1) in the RefSeq database (Figure 2.6a). Although none of 
the sequenced RACE clones yielded the 3’ ends from the two RefSeq isoforms, we were 
able to identify a 3’ end that had been predicted by several isoforms in the Ensembl 
database (e.g., ENST00000648773.1). There are currently 61 different LUCAT1 isoforms 
annotated in Ensembl (release 99). We cloned LUCAT1 transcripts using primers specific 
to the 5’ and 3’ ends that have been determined by RACE as well as a 3’ primer for the 
longer isoform NR_103548.1. Sequencing of these clones confirmed their expression in 
hMDDCs. Figure 1f depicts the 14 distinct LUCAT1 isoforms we detected (Figure 2.6b). 








Figure 2.6  Putative isoforms of LUCAT1. a Schematic showing sequences of identified 
3’ and 5; ends of LUCAT1 isoforms with RACE. b Schematic showing identified and 


















Engagement of TLR4 following LPS stimulation leads to activation of MyD88-
dependent and TRIF-dependent signaling pathways that culminate in the activation of NF-
κB and IRF3, critical transcription factors that control expression of immune response 
genes and type I IFNs. To evaluate the contribution of NF- κB and the IFN-I pathway in 
the inducible expression of lncRNA LUCAT1, we used Bay11-7082, an irreversible 
inhibitor of the IKK kinases, and Tofacitinib, a JAK1/JAK3 inhibitor (which would block 
signaling from the receptor for type I IFNs amongst other pathways). hMDDCs were 
preincubated with these inhibitors and then treated with LPS for 2 hours. RT-qPCR 
analysis showed that the inducible expression of LUCAT1 was significantly impaired using 
either NF- κB or JAK inhibition in a dose-dependent manner (Figure 2.7a-b). The levels 
of IL-6, an NF-κB regulated gene were dose dependently blocked by Bay11-7082, while 
the levels of the ISG RSAD2 were blocked by JAK inhibition as positive controls in these 
assays (Figure 2.7c-d). Collectively, these results indicate that LUCAT1 is induced by 





Figure 2.7 Inducible expression of LUCAT1 is impaired by inhibition of JAK-STAT1 
and NF-kB pathway. a hDCs were pretreated with NF-κB inhibitor Bay 11 followed by 
LPS stimulation. RT-qPCR analysis showing LUCAT1 expression in hDCs. (n=3, one-
way ANOVA Dunnett’s multiple comparisons test) b hDCs were pretreated with JAK1 
inhibitor Tofacitinib followed by LPS stimulation. RT-qPCR analysis showing LUCAT1 
expression in hDCs (n=3, one-way ANOVA Dunnett’s multiple comparisons test . Data is 
represented as ± SEM, ** P ≤ 0.01, **** P ≤ 0.0001. c RT-qPCR analysis of IL6 expression 
in primary hDCs cells stimulated with 200ng/ml LPS and NF-κB  inhibitor Bay11 at .1uM, 
.3uM and 1uM concentrations (n=3, one-way ANOVA Dunnett’s multiple comparisons 
test). d RT-qPCR analysis of RSAD2 expression in primary hDCs cells stimulated with 
200ng/ml LPS and JAK1 inhibitor Tofacitinib at .1uM and .3uM  concentrations (n=3, one-
way ANOVA Dunnett’s multiple comparisons test. Data is represented as ± SEM * P ≤ 
0.05,**** P ≤ 0.0001 
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LUCAT1 deficiency leads to hyperactivation of an inflammatory and ISG signature 
We next wanted to evaluate the possibility that LUCAT1 was a regulator of the 
inducible inflammatory response. Given, the challenges in generating primary human 
transgenic cells, we have made use of a novel CRISPR/Cas9-based approach, so-called 
Nanoblades [224], to target LUCAT1 in primary human cells. Nanoblades are engineered 
murine leukemia VLPs loaded with Cas9/sgRNA ribonucleoproteins[224]. By transfecting 
HEK-293T cells with plasmids encoding Gag:Cas9, Gag-Pro-Pol, a single-guide RNA 
(sgRNA), and viral envelopes, fusogenic VLPs are produced and released in the culture 
medium. Human DCs were incubated with Nanoblades loaded with two sgRNAs per 
combination and three different groups of Nanoblades were used for targeting the genomic 
locus and excision of LUCAT1 (Figure 2.8a). Using RT-qPCR analysis of targeted 
polyclonal cells we found that there was effective deletion of LUCAT1 in LPS-stimulated 






Figure 2.8: Schematic showing LUCAT1 targeting by Nanoblades. 
a Schematic showing LUCAT1 sgRNA encapsulated in Nanoblade VLPs. Three different 
combination of sgRNA were used to excise out LUCAT1. b RT-QPCR analysis for 
LUCAT1 gene expression in hDCs upon LPS stimulation in control, N1, N2, and N3 (n=3, 
one-way ANOVA Dunnett’s multiple comparisons test. Data is represented as ± SEM ** 




































To assess the impact of LUCAT1 deletion on the transcriptome, we used RNA 
sequencing to evaluate basal and LPS-inducible gene expression in LUCAT1 sufficient 
and deficient hMDDCs. RNA-seq analysis showed tight correlation between two technical 
replicates in all NTC control and LUCAT1 Nanoblades N1, N2, N3 at both resting state 
and LPS treated hMDDC (Figure 2.9a). Gene Ontology (GO) enrichment analysis showed 
enrichment of inflammatory response genes all of which were elevated in cells lacking 
LUCAT1 (Figure 2.10a).  The most differentially regulated genes included IFN-β as well 
as the IFN stimulated genes ISG15, IFITM3, IFIT3, IFIH1, IFI44 and CCL5 in all three 
Nanoblade combinations (Figure 2.10b-c). This observation was consistent with the 
findings that LUCAT1 depletion only lead to hyper activation of a subset of inflammatory 
genes, as several immune and non-immune genes were unchanged between the two groups 
(Figure 2.10d). We also validated these findings in hMDDC using RT-qPCR by measuring 
IFN-β (Figure 2.11a) and using Nanostring to measure the expression of a panel of 50 
inflammatory and IFN stimulated genes (Figure 2.11b). The Nanostring analysis showed 
elevated levels of IFN-β, ISGs and inflammatory response genes in all three Nanoblade 
sgRNA combinations following LPS stimulation relative to NTC cells treated with LPS 





Figure 2.9 : Correlation between RNA sequencing runs in LUCAT1 deficient cells  
a Scatter plot analysis showing correlation between two RNA sequencing runs in 

































Figure 2.10: LUCAT1 deficiency leads to hyperactivation of an inflammatory and 
ISG signature. Nanoblades were used to generate LUCAT1 deficient hDCs using three 
combinations of sgRNA; Nano1 (N1), Nano2 (N2) and Nano3 (N3). a Gene Ontology 
analysis showing enrichment of immune pathways in Nanoblade mediated LUCAT1 
depleted hDCs in LPS stimulated conditions. Unbiased RNA sequencing was performed 
in Nano1, Nano2, Nano3 and NTC hDCs. b Scatterplot analysis showing differentially 
regulated genes in FPKM values LUCAT1 Nanoblade hDCs compared to NTC controls in 
LPS stimulated conditions. c Bar graph representation of top pro inflammatory genes (in 
FPKM) differentially regulated between Nanoblade targeted LUCAT1 hDCs and NTC 
controls in LPS stimulated conditions. d Bar graph representation of genes (in FPKM) that 
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Figure 2.11: LUCAT1 deficiency leads to hyperactivation of an inflammatory and 
ISG signature 
a RT-QPCR analysis of IFNβ expression in Nanoblade mediated LUCAT1 targeting in 
hDCs cells upon LPS stimulation (n=3, Nano1 (N1), Nano2 (N2) and Nano3 (N3, one-way 
ANOVA Dunnett’s multiple comparisons test). Data is represented as ± SEM ** P ≤ 0.01 
b Heatmap analysis of inflammatory Nanostring code-set data representing the most 
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 We also confirmed these findings using a different cell system. We used 
Nanoblades to target LUCAT1 in THP-1 cells which resulted in efficient deletion of 
LUCAT1 (Figure 2.12a). RT-qPCR analysis of these cells showed an elevated IFN-β and 
CXCL10 response following LPS stimulation in LUCAT1-depleted cells when compared 
to NTCs (Figure 2.12b-c). The elevated expression of IFN-β and CXCL10 mRNA was also 
seen at the protein level in these LUCAT1 knock out THP-1 cells as compared to control 
cells upon LPS stimulation (Figure 2.12d).  
We also generated short hairpin RNA (shRNA)-expressing THP-1 cells targeting 
LUCAT1 RNA. THP-1 expressing shRNA showed more than 50 percent knock down of 
LUCAT1 (Figure 2.13a). Consistent with our findings using CRISPR-based Nanoblades, 
we observed a large increase in expression of IFN-β and IL-6 in these cells while the 
inducible levels of TNF-α were comparable between cell lines (Figure 2.13b-d). A heatmap 
showing the most differentially regulated genes measured using Nanostring is shown in 
(Figure 2.13e). Similar studies were performed using LUCAT1 shRNA-expressing 
BLaER1 cells. Optimal knock down of LUCAT1 resulted in elevated IFN-β expression in 







Figure 2.12: LUCAT1 deficiency leads to hyperactivation of an inflammatory and 
ISG signature in THP-1 cells. Nanoblades were used to generate LUCAT1 deficient THP-
1 using two combinations of sgRNA; Nano1 (N1) and Nano2 (N2). a-c RT-QPCR analysis 
for LUCAT1 (a), IFNβ (b) and CXCL10 (c) gene expression in THP-1 upon LPS 
stimulation (n=2; unpaired t-test)  d Culture supernatant was analyzed by ELISA for 
CXCL10 levels in LPS stimulated LUCAT1 KO THP-1 cells at 6hr time point. (n=3; 







        
Figure 2.13: LUCAT1 deficiency leads to hyperactivation of an inflammatory and 
ISG signature in LUCAT1-shRNA expressing THP-1 cells. RT-qPCR analysis of 
LUCAT1 (a), IFNβ (b), IL6 (c) and TNF-α (d) gene expression in LUCAT1 shRNA 
expressing THP-1 cells upon LPS stimulation (n=3; unpaired t-test). i Heat map 
representing top differentially regulated genes using Nanostring analysis for a code set of 
































































































































Figure 2.14: LUCAT1 deficiency leads to hyperactivation of an inflammatory and 
ISG signature in LUCAT1-shRNA expressing BlaER1 cells 
a RT-qPCR analysis of LUCAT1 gene expression in LUCAT1 shRNA expressing BlaER1 
cells upon LPS stimulation(N=2). b RT-qPCR analysis of IFNβ expression represented as 
fold change over NT in LUCAT1 shRNA expressing BlaER1 cells upon SeV 
stimulation(N=4, unpaired t-test). c RT-qPCR analysis of IFNβ expression represented as 
fold change over NT in LUCAT1 shRNA expressing BlaER1 cells upon LPS stimulation 
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Next, we performed gain-of-function studies to over express LUCAT1 from its 
endogenous locus. THP-1 cells expressing catalytically inactive Cas9 (dCas9) fused to the 
transcriptional activator VP64 were transduced with sgRNA containing viral supernatant 
and selected for puromycin resistance. CRISPRa-mediated over expression is enabled by 
recruitment of transcription coactivators to target gene loci [225]. Five LUCAT1 targeting 
sgRNA were designed within -200bp of the transcription start site (TSS). These gRNAs 
led to at least a 3-fold enhancement of LUCAT1 expression in THP1 cells (Figure 2.15a). 
When these cells were then challenged with LPS and SeV we observed a significant 
decrease in inducible IFN-β gene expression compared to the control sgRNA expressing 
cell lines (Figure 2.15b-c). These results indicate that expression of LUCAT1 reduced the 






Figure 2.15: LUCAT1 over expression in THP-1-VP64 cells. LUCAT1 was 
overexpressed form its endogenous loci using VP64 THP-1 cells. Five sgRNA were 
designed from -200bp to TSS to overexpress LUCAT1. a RT-QPCR analysis of LUCAT1 
gene expression in resting THP-1 VP64 LUCAT1 over expressing cells (N=2). b-c RT-
QPCR analysis showing IFNΒ expression upon LPS stimulation (b) or SeV infection (c) 
in THP-1 VP64 LUCAT1 over expressing cells. (n=2, one-way ANOVA Dunnett’s 
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LUCAT1 is enriched in nuclear compartment upon activation, and is associated with 
active chromatin markers 
Defining the cellular distribution of lncRNAs is crucial to understand their 
biological function [226]. A large proportion of lncRNAs are retained in the nucleus where 
they regulate chromatin structure and accessibility as well as transcription of target genes 
[226, 227]. In order to define the localization of LUCAT1 we prepared nuclear and 
cytoplasmic fractions of LPS-stimulated THP-1 cells and measured LUCAT1 levels in 
these fractions by RT-qPCR. We observed enrichment of LUCAT1 in the nuclear 
compartment in LPS treated cells (Figure 2.16a).  
To validate and expand on these findings we next performed single-molecule RNA 
fluorescence in situ hybridization (smFISH) on hMDDCs which confirmed these findings. 
While there were low levels of LUCAT1 in cells in the absence of stimulation, the levels 
of LUCAT1 increased and were enriched in the nucleus upon stimulation in primary 
hMDDC (Figure 2.17a). We observed a speckled staining pattern of LUCAT1 in the 
nucleus, which was significantly higher in cells treated with LPS than in resting cells 
(Figure 2.17b).  
We next performed RNA immunoprecipitation (RIP) using Histone H3 antibody to 
determine if LUCAT1 was enriched in the chromatin fraction of cells. Indeed, histone H3 
RIP followed by RT-qPCR analysis, showed enrichment of lncRNA LUCAT1 following 
LPS stimulation.  This was similar to what we found for MALAT1, a known chromatin-
bound lncRNA [228] (Figure 2.18a). Together, these findings clearly indicate the presence 






Figure 2.16: LUCAT1 is enriched in nuclear compartment upon LPS activation in 
THP-1 cells. RT-qPCR analysis of GAPDH, LUCAT1 and MALAT1 gene expression in 





































Figure 2.17: LUCAT1 is enriched in nuclear compartment upon activation in hDCs. 
a smFISH analysis for LUCAT1 in primary human hDCs in stimulated conditions. 
LUCAT1 probes are represented in red, chromatin staining by DAPI in blue and GAPDH 
mRNA in green b Quantification of LUCAT1 puncta in smFISH imaging in a ** P ≤ 0.01 
(unpaired t-test). c smFISH analysis for LUCAT1 in primary human hDCs in stimulated 
conditions. LUCAT1 probes are represented in red, chromatin staining by DAPI in blue 




     


































Figure 2.18: LUCAT1 is associated with active chromatin markers 
a-b RT-qPCR analysis of LUCAT1 and MALAT1 gene expression in RNA 
immunoprecipitation (RIP) samples using antibody against Histone H3 (n=4, unpaired t-

































































































Transcriptional regulation of IFN-I and ISGs by LUCAT1 and identification of 
STAT1 as a binding partner of lncRNA LUCAT1 
We next wanted to understand if LUCAT1 was acting to alter transcription of IFN-β and 
ISGs. We performed Chromatin Immunoprecipitation (ChIP) followed by qPCR to assess 
the recruitment of RNA polymerase II (RNA pol II) and H3K4 trimethylation, a marker 
active transcription at target gene loci. The recruitment of RNA pol II to the promoters of 
the IFN-β and RSAD2 genes was significantly enhanced in cells stimulated with LPS 
(Figure 2.19 a,b). When LUCAT1 levels were reduced by shRNA, there was increased 
RNA pol II binding at the promoters of both IFN-β and RSAD2 genes compared to control 
cells indicating that the increased expression of IFN-β and ISGs was likely due to increased 
transcription of these target genes. Similarly, there was an increase in H3K4me3 observed 
at the promoter of IFN-β and RSAD2 in LUCAT1 deficient cells in both untreated and LPS 
stimulated conditions (Figure 2.19 c,d).  
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Figure 2.19: Transcriptional regulation of IFN-I and ISGs by LUCAT1  
a-b ChIP qPCR analysis of Pol II at IFNβ (a) and RSAD2 (b) promoter in THP-1 cells 
expressing LUCAT1 shRNA in LPS stimulated conditions (N=2). c-d ChIP qPCR analysis 
of H3K4me3 at IFNβ (c) and RSAD2 (d) promoter in THP-1 cells expressing LUCAT1 
shRNA in LPS stimulated conditions (n=2, unpaired t-test). Data is represented as ± SEM 
** P ≤ 0.01. 
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These observations suggest that LUCAT1 normally restrains the transcription of 
IFN-β and ISGs. To better understand how LUCAT1 might mediate this effect we wanted 
to identify protein binding partners of LUCAT1 in the chromatin fraction of cells. We 
performed comprehensive identification of RNA-binding proteins by mass spectrometry 
(ChIRP-MS) in primary hMDDCs [130]. LPS-treated primary cells were chemically 
crosslinked and sonicated to achieve optimal RNA fragments. Cell lysates were then 
incubated with biotinylated ssDNA probes that were antisense to LUCAT1 and enriched 
using streptavidin beads. Proteins associated with these complexes were then identified by 
Mass Spectrometry (Figure 2.20). Proteomics analysis of untreated vs LPS treated samples 
revealed many nuclear proteins specifically enriched in LPS treated samples (Figure 
2.21a). Amongst the most enriched LUCAT1 binding proteins we identified STAT1. In 
order to confirm our ChIRP findings, we performed RNA immunoprecipitation using 
STAT1 antibody. RIP confirmed LUCAT1 binding to STAT1 (Figure 2.21b). We used 
antibody to IRF3 and IgG as a control and found no enrichment of LUCAT1 in IRF3 or 
IgG control conditions. Collectively, these results indicate that LUCAT1 binds to STAT1 









Figure 2.21: Identification of LUCAT1 interactions with nuclear proteins and 
validation of STAT1 as a binding partner  
a Bar graph representing spectral counts of top 10 nuclear proteins pulled down in ChIRP 
using ssDNA probes against LUCAT1 (N=2 donors). b RNA Immuno-precipitation (RIP) 
was performed on human DCs using STAT1 and IRF3 antibodies.  RT-QPCR analysis for 



























































































LncRNA LUCAT1 is induced by the Krebs Cycle metabolite itaconate in an NRF2-
dependent manner 
It was recently shown that type I IFNs increase expression of IRG1 leading to 
elevated levels of itaconate in murine macrophages [101]. The anti-inflammatory effect of 
itaconate can be mimicked by its cell-permeable derivate 4-octyl itaconate (4-OI), which 
is able to decrease both IL-1  and type I IFN responses. We confirmed that 4-OI reduces 
LPS-induced IFN-b levels and 4-OI treatment increased expression of LUCAT1 in human 
DCs (Figure 2.22 a,b). Itaconate-mediated shut down of IL-1 was shown to be dependent 
on the transcription factor NRF2. Yet, how itaconate shuts down type I IFNs and how this 
impacts anti-viral immunity has not been examined to date. It was previously shown that 
LUCAT1 expression is regulated in an NRF2-dependent manner[215, 229]. By examining 
ChIP-seq data in A549 airway epithelial cells, we confirmed that NRF2 binds to the 
LUCAT1 promoter region (Figure 2.23a). Consistent with this finding, ChIP-PCR for 
LUCAT1 promoter also confirmed NRF2 specific binding in THP1 cells (Figure 2.23b). 
Additionally, induction of LUCAT1 was lost in primary hMDM cells expressing siRNA 
for NRF2 (Figure 2.23c). Collectively, these findings indicate that LUCAT1 directs the 
anti-inflammatory effects of the Itaconate and may highlight a novel mechanism of ISG 






Figure 2.22: Itaconate induces expression of LUCAT1 in primary human immune 
cells.   
a.RT-PCR analysis of LUCAT1 gene expression in hDCs treated with 4-OI and LPS at 
2hrs b. RT-PCR analysis of LUCAT1 gene expression in hMDMs treated with 4-OI in a 
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Figure 2.23: Expression of lncRNA LUCAT1 is dependent on NRF2  a.Genome 
browser view showing NRF2 CHIP binding on LUCAT1 promoter in A549 cells. b. 
CHIP-PCR for LUCAT1 gene expression in NRF2-CHIP samples in THP-1 cells treated 
with 4-OI c. RT-PCR analysis of LUCAT1 gene expression in 4OI treated hMDMs with 




























ER-621 S CACCGGTACATCGTTAGATTTGAAA 
ER-622 AS AAACTTTCAAATCTAACGATGTACC
ER-623 S CACCGATATTGAAGCGAGCACCTCA 
ER-624 AS AAACTGAGGTGCTCGCTTCAATATC
ER-625 S CACCGGACTTGCCACCCTGGTTGAT 
ER-626 AS AAACATCAACCAGGGTGGCAAGTCC
ER-627 S CACCGGACGGCTGAAAATTGCTGAC 
ER-628 AS AAACGTCAGCAATTTTCAGCCGTCC
ER-629 S CACCGAGGCTTCAAAGGGTTATGGG 
ER-630 AS AAACCCCATAACCCTTTGAAGCCTC
ER-631 S CACCGGGGACGTGGGAGGCTTCAAA 
ER-632 AS AAACTTTGAAGCCTCCCACGTCCCC

















shRNA hairpin sequences 
Nanoblade sgRNA sequences 
CRISPRa sgRNA sequences 






LUCAT1 ChIRP Probe 1 TGAGAGAAAAGAGGATGAAAGCTGTTCTTAAATTGCACCTGTCTAAGGCAATCCGAGCTTGACACATGGTTTCTGGAGGTCTGGGCATTG
LUCAT1 ChIRP Probe 2 TCTCTGGTGCCAAGGTCCCATAAGAGTTCCAGCTGGGTGAGCTTCTTGTGAGGAAAGGAGCCAGAAGTCAGAACACATAGTGTGACAATA
LUCAT1 ChIRP Probe 3 AACCAATTTTGTTAACGTGAGAGAAATACAAGAAAGCCAAGTCAGAAATACCATTGTTGCTGTTAGAAAACTTCAAAGAGGAATTTGTGG
LUCAT1 ChIRP Probe 4 GCAGTGAACCGAGATCGCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCGAAACTCTGTAGCTCAGCATGTAGCCCATGGTAGATGCTG
LUCAT1 ChIRP Probe 5 GGATTCCTGGGTGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGTGGAGCTT
LUCAT1 ChIRP Probe 6 CTCATCCTTCCAAAGACGTCAGTCACATTCAGCCCCTTTAGCAGTTTCATCAACAGCATGTATAGCACATGTGATAGCAAACAGCAAGTT
LUCAT1 ChIRP Probe 7 CTTATCTTCTGACATCTTCTGATGGGTTTTGTTCCTTTTCATTGGGAGATGAGGACAGCATTTGGACACAACTGTACAGGCACGCTAAGT
LUCAT1 ChIRP Probe 8 CCTCGGGTTGCCTCTGTTTATCCATCTCTCTTTTTTTAAGAAGTAGAACACTGAGGGACAGCTGGTAAGTGTAGCATCAGGACAAAAATC
LUCAT1 ChIRP Probe 9 AGGCTCTTTATTTGTGAGGGGATGAGAATACTGGCATCCATTGTGTCTTATTTAGTGACTGAAATGTGTGACACTGAGCAAGGCCTTTAT
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Discussion 
Type I interferons are a family of cytokines which function primarily to elicit 
immune responses against viruses and bacteria in an autocrine, paracrine and systemic 
manner. Activation of type I IFNs can also leads to cellular proliferation, differentiation 
and migration, all of which impacts type I IFN mediated pathogen clearance and restoration 
of homeostasis [230]. Although, activation of type I IFN imparts protective immunity, 
excessive production of type I IFN leads to chronic inflammation and tissue damage as 
characterized by many autoimmune disorders including systemic lupus erythematosus 
(SLE), Sjogren’s syndrome and Aicardi–Goutières syndrome (AGS) [231, 232]. Therefore, 
tight regulation of type I IFN responses is necessary to maintain immune homeostasis. The 
type I IFN response is mediated by binding of IFNα/β to the heterodimeric IFNα/β receptor 
(IFNAR1/IFNAR2) which results in phosphorylation of receptor associated tyrosine 
kinases, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). Phosphorylated TYK2 and 
JAK1 in turn phosphorylate and activate signal transducer and activators of transcription 1 
(STAT1) and STAT2 leading to the formation of STAT1/STAT2 heterodimers. The 
phosphorylated STAT1-STAT2 heterodimers translocate to the nucleus and form an IFN-
stimulated gene factor 3 complex (ISGF3) complex with IRF9 [48, 200, 233]. Binding of 
the ISGF3 complex to the promoters of IFN-stimulated genes (ISGs) is important for 
effective anti-microbial responses [48, 200, 201].   
JAK1-STAT signaling also leads to upregulation of various immunomodulatory proteins 
which act in a negative feedback manner to turn off the IFN-I signaling. Negative 
regulation of the type I IFN pathway involves numerous protein factors that act to limit 
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PRRs, PRR signaling and as well as IFN signaling itself. Suppressor of cytokine signaling 
(SOCS1 and SOCS3) proteins, specifically SOCS1 is a potent negative regulator of type I 
IFN signaling and functions by reducing TYK2 and STAT1 phosphorylation. SOCS1 
deficiency has been associated with increased ISG transcription, cytokine production and 
enhanced pathogen clearance in murine models [77, 234]. Similarly, Src homology 
phosphatase proteins (SHP1 and SHP2) inhibit phosphorylation of signaling molecules 
including STAT1 and JAK1 to down regulate type I IFN signaling [62]. Many negative 
regulators of type I IFN signaling bind to the receptor itself to alter the signal transduction 
cascade. USP18 is an example of one such protein that binds IFNAR1/IFNAR2 and 
displaces JAK1, thus altering its binding preference to low affinity IFNα, thereby 
decreasing the overall strength of type I IFN signaling [235, 236]. In addition to these 
protein regulators of the type I IFN response, a growing body of literature has identified 
non-coding RNAs including miRNAs and lncRNAs, that are co-expressed with ISGs. 
ncRNAs are known to have diverse roles in regulation of immune pathways including 
inhibiting type I IFN signaling by targeting STAT1 and STAT2 (miRNA 221/222), 
suppression of IFNβ production (miRNA miR26a, miR34a, miR145, and Let7b ) [237] and 
negative regulation of PRRs such as RIG-I (miRNA-146a) [238]. Additionally, lncRNAs 
such as lncRNA-CMPK2 has been shown to downregulate IFN-I response by acting in a 
negative feedback manner, however not many lncRNAs are known controlling IFN-I 
responses in human cells[161].  
Here, we have identified LUCAT1 as a novel immune signaling regulator that limits 
the type I IFN response in human myeloid cells. High throughput RNA sequencing 
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revealed LUCAT1 as one the most dynamically regulated lncRNAs in HSV-1, IAV- and 
LPS-stimulated hMDDCs as well as in other primary myeloid cells and cell lines. The role 
of LUCAT1 in regulation of type I IFN responses was further characterized by loss of 
function studies. Unbiased transcriptome analysis on LUCAT1-depleted primary hMDDCs 
showed an increased inflammatory gene signature that predominantly included numerous 
STAT1-regulated genes such as CCL5, IP10, IFIT and RSAD2.  We also observe 
differential regulation other inflammatory genes such as NF-κB-driven IL-6 and IL-10, 
suggesting a broader role of LUCAT1 in restraining immune responses. Additionally, we 
utilized CRISPRa to generate LUCAT1-overexpressing human monocytic cells. In contrast 
to loss-of-function studies, increased levels of LUCAT1 suppressed the expression of 
inflammatory genes and ISGs. A similar observation was made in a diabetic model of a 
human lung cell line, where overexpression of LUCAT1 led to decreased levels of iNOS 
and NO [239]. These results provide compelling evidence that LUCAT1 regulates an anti-
inflammatory program specifically by restraining the type I IFN and inflammatory 
response during acute phases of infection. 
Since lncRNAs impact biological process through a number of mechanisms, it is 
informative to understand where in the cell these RNAs are localized. Cellular localization 
dictates regulation and function [226, 240]. Numerous studies have shown that nuclear 
localized lncRNAs modulate chromatin state, transcription or RNA splicing In contrast to 
lncRNAs in the cytosol, that can interact with miRNAs, influence translation or interact 
with host proteins post-translational modifications [137]. Both cellular fractionation and 
smFISH in primary hMDDC confirmed that LUCAT1 is highly enriched in the nucleus 
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following stimulation. Nuclear-retained lncRNAs frequently associate with chromatin or 
with protein factors in the nucleus. RNA immunoprecipitation of LUCAT1 revealed 
enrichment of LUCAT1 with the histone subunit H3 confirming its association with 
chromatin. The data supported by RNA pol II and Histone H3K4 ChIP in LUCAT1-
deficient cells also suggests that LUCAT1 impacts transcription of its target genes.  
With the advancement in techniques to interrogate RNA-protein interactions more 
precisely, we performed ChIRP-MS to identify the protein binding partners of LUCAT1 in 
nuclear extracts from crosslinked cells. This approach identified STAT1 as a LUCAT1 
protein partner. STAT1 is a master regulator of the Type-I IFN response. Its 
phosphorylation in response to IFNα/β leads to its interaction with STAT2 and IRF9 to 
form the ISGF3 complex. This complex then translocates into the nucleus to bind 
Interferon stimulated response elements (ISRE) in the promoters of ISGs to facilitate their 
transcription. The increased expression of ISGs in LUCAT-1 deficient cells, indicates that 
LUCAT1 interacts with STAT1 to limit the transcription of ISGs. There are at least two 
possibilities by which this could occur. Firstly, LUCAT1 could sequester STAT1 in the 
nucleus preventing STAT1 binding to the promoters of ISGs. This would limit the ability 
of nuclear STAT1 to turn on ISG expression. Alternatively, LUCAT1 could associate with 
STAT1 on the promoters of ISGs and recruit chromatin modifying complexes or 
transcriptional repressors to alter chromatin state or block transcription of STAT1 target 
genes.  A better understanding of these mechanisms could highlight novel regulatory 
pathways for ISG regulation.  
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In human lung cancer, LUCAT1 has been proposed to be transcriptionally regulated 
by the NRF2 pathway in human lung epithelial cells [215].  NRF2 is a transcription factor 
that is activated in cells during oxidative stress or inflammatory response. In resting 
conditions, NRF2 is kept inactive and its association with KEAP1 ensures its rapid turnover 
in the cytosol. During events of stress, KEAP1 undergoes ubiquitination and alkylation 
mediated degradation, enabling NRF2 release and accumulation in the cytosol [101]. 
Activated NRF2 then translocates to the nucleus to initiate an anti-inflammatory and anti-
oxidative program [101]. Various studies have led to the finding that activation of immune 
responses simultaneously also initiates metabolic reprogramming. Recently, Mills et al  
showed that many metabolites accumulate during LPS challenge of primary BMDMs with 
itaconate being the most abundant of them [101]. Treatment of cells with a cell permeable 
derivate of itaconate, 4-OI, can activate NRF2 and its target gene expression. However, the 
question still remains pending as to how NRF2 regulates immune genes. Since LUCAT1 
is an NRF2 target gene, we wanted to explore the possibility of NRF2-LUCAT1 mediated 
effect on human immune response. Primary macrophages treated with 4-OI, a cell-
permeable derivate of itaconate, showed increased expression of LUCAT1 and NRF2 
genes. Both Nanoblade- and siRNA-mediated depletion of NRF2 resulted in complete 
suppression of lncRNA LUCAT1 in primary human macrophages. Further, NRF2 ChIP-
seq in A549 lung cells, revealed that activated NRF2 binds at the LUCAT1 promoter 
region. These finding were also confirmed by performing ChIP-qPCR in THP-1 cells to 
show NRF2 also binds to the LUCAT1 promoter in myeloid cells.  These results shed a 
 119 
light on the possibility of LUCAT1 regulation of immune genes via a metabolically 
activated NRF2 mediated pathway.  
Given the complexity of lncRNA regulation in a species specific manner, 
identification of human lncRNAs in innate immune pathways can highlight novel 
regulatory mechanisms. In summary, this study provides a unique intersection between 
transcriptional regulation of type-1 IFN pathways by a bonafide lncRNA LUCAT1 in 
human immune cells and its induction dependent on a metabolically activated NRF2 
pathway. Given the importance of metabolic reprogramming in events of immune 
challenge, non-coding RNAs such as LUCAT1 can serve as potential therapeutic targets to 






Leukoreduction system (LRS) chambers from healthy donors were obtained from 
New York Biologics. Peripheral blood mononuclear cells (PBMCs) were obtained from 
LRS chambers by Lymphoprep density gradient centrifugation (Stemcell Technologies). 
CD14 positive monocytes were isolated from PBMCs by magnetic cell separation (MACS) 
using CD14 microbeads (Miltenyi). Purity of isolated CD14 positive cells was determined 
using flow cytometry. 
 
Cell culture 
THP-1 cell line was obtained from ATCC and maintained in RPMI 1640 (corning) 
supplemented with 10% FCS and 1% Pen/Strep and were differentiated into macrophages 
in the presence of 10 ng/ml phorbol-12-myristate acetate (PMA, Sigma) for 12-16 hours 
followed by media change and resting for up to 48 hours. CD14+ monocytes were 
differentiated into monocyte-derived Dendritic Cells (hMDDCs) using a cocktail of hIL-4 
and hGMCSF (produced in 293T cells) in RPMI with 10% pooled human AB serum 
(Sigma) for 7-8 days. CD14+ monocytes were also differentiated into monocyte derived 
Macrophages (hMDMs) using hM-CSF (Peprotech, Human Recombinant M-CSF, #300-
25) in RPMI with 10% pooled human AB serum (Sigma) for 5-6 days. 
BlaER1 were obtained from Dr. Viet Hornung laboratory, Munich [222, 241]  and cultured 
in RPMI, 10%FCS, 1% Glutamine, 1% Pyruvate + 1% Pen/strep. For differentiation, 10^5 
cells  in culture media in 96 well plate supplemented with 10 ng/ml of hrIL-3 (PeproTech), 
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10 ng/ml hr-CSF-1 (M-CSF) (PeproTech) and 100 nM β-Estradiol (Sigma-Aldrich) and 




Cytokine levels in supernatants were measured by CXCL10 ELISA (R&D 
Systems) according to the manufacturer’s instructions. 
 
Reagents 
Reagents used in the study were obtained from following sources: E. coli LPS, was 
purchased from Sigma-Aldrich (St. Louis, MO); recombinant human M- CSF (Peprotech, 
Inc.), NF- κB inhibitor BAY-7082 (Tocris Bioscience), Tofacitinib (Sigma), HSV-1 
(David Knipe Laboratory) Sendai virus (Cantrell strain) was purchased from Charles River 
Laboratories (Wilmington, MA), GeneJuice was from Novagen (Madison, WI). 
Customized nCounter gene expression code-set was obtained from NanoString 
technologies (Seattle, WA).  
 
RNA sequencing and Bioinformatics 
Primary human DCs were treated with HSV-1 at MOI-10, IAV at MOI .5 and LPS 
(200ng/ml) for 2hr and 6hr. Cells were washed with cold PBS once and scraped. Pelleted 
cells were lysed in lysis buffer followed by RNA extraction according to manufacturer’s 
protocol (Bio-Rad Aurum Total RNA mini Kit, #7326820). Strand-specific total RNA, 
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with depletion of rRNA, libraries were generated with 1 µg of input RNA using the TruSeq 
Stranded Total RNA Sample Prep Kit (Illumina) and sequenced on an Illumina HiSeq 
machine. Paired-end sequence reads were aligned to the masked human genome using 
Bowtie [242] and expression analysis was performed with RSEM [243] and EBSeq [244]. 
The RSEM-calculate expression program was run with --paired-end --forward-probe 
options and GTF version 84 from Ensembl. The EBSeqHMMTest function was used to 
calculate posterior probabilities for potential expression patterns in the time course 
experiment. The false discovery rate of genes was controlled at 5%, which corresponds to 
a posterior probability of 0.95 or greater. A pseudo value of one was added to TPM values 
prior to log transformations and calculation of fold-change values. The data was deposited 
into GEO SuperSeries GSE14545. 
 
RNA sequencing on LUCAT1 Nanoblade clones in primary human DC samples  
1µg of Total RNA from LUCAT1 Nanoblade clone and control cell stimulated with 
LPS was sent to BGI for high through put RNA sequencing. The sequence reads were 
aligned to human reference genome build hg19 using TopHat2 [245] and Bowtie2 [242]. 
FPKM (fragments per kilobase million) values were computed using Cufflinks and fold 
changes were calculated using Cuffdiff [246] . Gene Ontology enrichment was performed 





Rapid amplification of cDNA ends (RACE) and cloning 
RACE was performed using SMARTer RACE kit (Takara Bio) according to the 
manufacturer’s instructions using RNA from hMDDCs stimulated for 2 hours with 200 
ng/ml LPS. Briefly, after cDNA generation, 3’ and 5’ ends were amplified using SeqAmp 
DNA polymerase and gene-specific primers (for 3’ RACE: 5’-
gattacgccaagcttGTCAAGCTCGGATTGCCTTAGACAGGTGCA-3’ and for 5’ RACE 
5’gattacgccaagcttAGGGACAGCTGGTAAGTGTAGCATCAGG-3’). Products were gel-
purified, cloned into the pRACE vector and transformed into Stellar competent cells. 
Plasmids were isolated from single clones and sequenced at Sequegen (Worcester, MA). 
LUCAT1 was cloned from 5’ RACE cDNA using Q5 Polymerase (NEB) with a 5’-specifc 
primer with a XhoI recognition site (5’-
ataccgctcgagAATCAACACTCCACTCAGACAATGCC-3’) and two different 3’-
specifca primer with EcoRI recognition sites (Primer for the short isoform: 
5’aggaattcTGAGACAGAGTCTCACTCTGTTGCC-3’; and primer for the long isoform: 
5’aggaattcGTATCTGCCTTTTCAGGCAGTGAAATC-3’). The amplicons were cloned 
into PMSCV-PIG vector (addgene, #21654) using XhoI and EcoRI (NEB), transformed 
into Stbl3 competent cells and sequenced at Genewiz (Cambridge, MA). 
 
RNA Isolation and RT-qPCR 
Total RNA was isolated using Aurum Total RNA mini kit (Bio-Rad Laboratories). 
RNA concentration was determined using a spectrophotometer (Nanodrop, Thermo Fisher) 
and RNA with an A260/A280 ratio >2.0 was considered as pure. RNA was reverse 
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transcribed using iScript cDNA Synthesis Kit and quantitative PCR was performed using 
iTaq Universal SYBR green supermix (both Bio-Rad Laboratories) according to 
manufacturer’s instructions. Fold change in mRNA expression was calculated using the 
comparative cycle method (2^-dCT) normalized to the housekeeping gene GAPDH or 
HPRT. LUCAT1 copy numbers were calculated using standard curves of LUCAT1 RT-
qPCR products.  List of primer in Table 1 
 
Loss of Function studies 
For RNA interference studies, short hairpin RNAs (shRNA) targeting Exon 1 of 
LUCAT1 and non-targeting control shRNA were cloned into the pLKO vector( addgene 
#8453). 4 µg of pLKO were transfected into HEK293T cells together with packaging 
vectors 1 µg pxMD2.G (Addgene, #12259) and 3 µg psPAX2 (Addgene, #12260) in 10cm 
dishes using GeneJuice(Millipore, #70967-6). After, 48 and 72 hours the supernatant was 
collected and lentivirus was concentrated using LentiX Concentrator (CloneTech) 
according to the manufacturer’s instructions. 100 µl of concentrated virus was added to 2 
X 10^6  THP-1 cells for 48 hours in presence of 8µg/ml polybrene, followed by 2µg/ml 
puromycin (Corning, 61-385-RA) selection for 4-5days. List of sequences in Table 1. 
 
Gain of function studies 
To create LUCAT1 over expressing cells, Vp64 expressing THP-1 cells were used 
(Dr. Patrick McDonel and Dr. Manuel Garber laboratory).  sgRNA were designed within -
200 bp to 0 bp relative to the TSS of LUCAT1 and cloned in 6 µg lentiguide puro vector 
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(addgene, #52963) and transfected into HEK293T cells with packing vectors- vectors 2 µg 
pxMD2.G (Addgene, #12259) and 4 µg psPAX2 (Addgene, #12260) using GeneJuice 
(Millipore, #70967-6). After 48h of culture, the culture media was isolated and 
concentrated for lentivirus using LentiX concentrator (Clonetech). 100 µl of concentrated 
virus was added to 2 X 10^6  THP-1 cells for 48 hours in presence of 8µg/ml polybrene, 
followed by 2µg/ml puromycin (Corning, 61-385-RA) selection. List of sequences are 
indicated in table 1. 
 
NanoString analysis  
Cell stimulation and RNA isolation was performed as described above. The 
nCounter analysis system was used for multiplex mRNA measurements using a previously 
described custom gene expression code-set against 250 pro-inflammatory genes. Total 
RNA (100 ng) was hybridized overnight with the gene expression code-set and analyzed 
on an nCounter Digital Analyzer (Nanostring Technologies). RNA hybridization, data 
acquisition and analysis was performed as per manufacturer’s specifications. RNA counts 
were processed to account for hybridization efficiency, and mRNA expressions across 
experimental groups were normalized to the geometric mean of six housekeeping genes.  
 
Chromatin Immunoprecipitation 
After stimulations, the cells were fixed with 1% formaldehyde, lysed, and sheared. 
The DNA was quantified, and 5 mg of total chromatin was immunoprecipitated with 
specific antibodies and Dynabeads Protein G (Novex/Life Technologies #10009D). The 
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DNA was then reverse cross-linked, purified, and quantitated by quantitative PCR (qPCR) 
amplification with primers designed at the promoter sites of the IFNΒ (F-5’-
TCGTTTGCTTTCCTTTGCTT-3’, R-5’-CCCACTTTCACTTCTCCCTTT-3’) and 
RSAD2 (F-5’-CCTGGCATACAGGACACCTT-3’, R-5’ 
AAGAGTTCTGTCCGCTTCCA- 3’)genes. Antibodies used were against RNA 
Polymerase II (RNA Pol-II; Active Motif #39097), Histone H3 trimethylated at Lysine 4 
(H3K4me3; Abcam # ab8580), or control IgG isotype (Abcam # ab37415 or Cell Signaling 
Technology #5415). Data was calculated as the percentage fraction of total input DNA, 
using IgG isotype as control. 
 
Nanoblades 
Nanoblades were produced as described by Mangeot, P. E et al [248]. Briefly, 
HEK293T cells were plated at 70%-80% confluency in a 10 cm dish in 10 ml of Glutamax 
DMEM with 10% FBS and 1% pen/strep.  0.3 µg VSV-G, 0.7 µg BRL, 2.7 µg 5349, 1.7 
µg BicCas9, 2.2 µg Blade for LUCAT1 sgRNA1, 2.2 µg Blade for LUCAT1 sgRNA2 were 
transfected in HEK293T cells using JetPrime (Polyplus Transfection) according to the 
manufacturer’s instructions. VLP Nanoblade-containing supernatant was collected 40h 
post transfection, centrifuged at 500g for 5min and filtered using a .45 µm syringe filter to 
remove cells and debris. Nanoblades were pelleted by ultracentrifugation at 35000 rpm on 
a SW41 rotor for 1.5h and the pellet was resuspended in 100 µl of PBS. For LUCAT1 
deletion, primary hDCs were plated in 12 wells plates with 1.5 million cells per condition 
in 400 µl of hDCs conditioned medium as described above. 40µl of resuspended 
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Nanoblades were added per well and incubated at 37 °C for 4-5 h followed by careful 
addition of 600 µl of fresh medium. The cells were incubated with Nanoblades for 48 h 
followed by stimulation and RNA/Protein analysis as described above. List of sequences 
in table-1. 
 
FISH and Confocal Microscopy 
Fluorescence In-Situ Hybridization (FISH) was carried out using ViewRNA ISH 
Cell Assay (Thermo Fisher) according to the manufacturer’s protocol. Primary human DC 
cells were incubated on coverslips in culture dishes with or without LPS stimulations. The 
cells were probed for LUCAT1 (Alexa647) and GAPDH (Alexa488) mRNA. The cells were 
fixed and visualized using confocal microscopy (Leica 8000) at 40x magnification for 
abundance and localization. Data was quantified as the average number of puncta observed 
in the cells. 
 
Pulse Chase 
Pulse chase was performed as described in Garibaldi et al. [223] 1.5 million primary 
human DCs were plated in 6 well plate and stimulated with LPS simultaneously with 
addition of 500 µM 4SU in the media for 30min, 1hr, 2hr and 4hrs. The reaction was 
quenched by rapid addition of trizol at the end of each time point followed by RNA 




Biotinylation of 4SU RNA 
4SU RNA was incubated with 2µl Biotin-HDPD (1mg/ml) per 1 µg RNA and 1µl 
Biotinylation buffer per 1 µg RNA at room temperature in dark for 1.5 hours. Post 
incubation, RNA was extracted using Phenol/chloroform extraction and resuspended at 1 
µg /µl concentration. 
Separation of labelled RNA  
Biotinylated samples were heated at 65C for 10min and immediately placed on ice 
for 5min. 100µg of RNA was added to 100µl of streptavidin beads and incubated at room 
temperature for 15min. µMACS columns were used for recovery of streptavidin-biotin 
labelled RNA. µMACS columns were placed on magnetic stand and equilibrated using 
wash buffer before putting labeled RNA. After 3 subsequent washes, RNA was eluted 
using 100µl of 100mM DTT solution twice followed by EtOH precipitation. The resulting 
RNA was then analyzed for gene expression using RT-qPCR. 
 
RNA fractionation 
THP-1 cells were fractionated into cytosolic and nuclear compartments using 
detergent lysis method (Tsai et al., 2010). RNA was purified from individual fractions 
using TRIzol (Ambion) and reverse transcribed with oligo-dT primers using the cDNA 
synthesis kit (Agilent), and subjected to qPCR analysis. Expressions of target genes in 
individual fractions were normalized to their expression level in the input RNA, which was 
set as 100%.  
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ChIRP – MS 
Cell lysis and sonication: ChIRP-MS was performed according to the protocol from 
chu et al. 50-60 million primary human DCs were plated in 15cm dishes in 15ml primary 
human DC media and stimulated 200ng/µl with LPS for 2 hours. Post stimulation, cells 
were washed and collected in 50ml conical tubes followed by chemical crosslinking using 
3% formaldehyde for 30min at room temperature.  The cells were quenched using .5M 
Glycine for 15 min at room temperature. Cells were then pelleted by spinning at 2000 RCF 
for 3min at room temperature. Cell pellet was then resuspended in lysis buffer and 
sonicated using water bath bioruptor  in a 4°C water bath at highest setting with 30 seconds 
ON, 45 seconds OFF pulse intervals. The lysates were then centrifuged at 16100RCF for 
10min at 4C and flash frozen in liquid nitrogen.  
Hybridization: Sonicated cell lysates in the above step were thawed at room 
temperature and 10% of lysates were removed and reserved as Input Controls. 2ml of 
Hybridization buffer was added to each sample along with 1µl of 100µM Control and 
LUCAT1 probes (List of ChIRP probes in Table 2). The probes-lysate mix was then 
incubated at 37C for 4 hours followed by addition of washed C1-magnetic beads (100µl 
C1 beads to 100pmol of probes) to the hybridization mix and  incubated for 30min. 
Subsequently, the beads were magnetically separated and washed for 5 times total and 
diluted in 1ml of wash buffer. 100µl of resuspended beads were used for RNA extraction 
and 900µl for protein.  
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For RNA extraction: 100µl of beads were magnetically separated and resuspended 
in PK buffer followed by heated shaking at 50C for 45min. RNA was extracted using 
TRIzol as per manufacturer’s protocol. 
Sample preparation for Mass Spectrometry samples:  
Primary human DC samples from two independent donors stimulated with LPS and 
pulled down suing control and LUCAT1 probes were prepped for Mass Spectrometry. 
Samples were boiled Boil in SDS-PAGE loading buffer in 35µl volume and the entire 
reaction was loaded onto a pre-cast SDS-PAGE gel (Invitrogen or Bio-Rad minigel). The 
samples were ran till the dye front reached ~1.5cm into the gel, stained and de-stained with 
Coomassie. Excision of band  and Mass spectrometry was performed at the University of 
Massachusetts MS core facility (https://www.umassmed.edu/MSF/) . 0.2pmol of yeast 
ADH digest was spiked into each of the samples and were run in technical. 
 
Generation of THP-1 LUCAT1-KO cell line 
THP-1 KO cell lines were generated using lentiviral transfer gRNAs into Cas9-
expressing THP-1 cells. For lentiviral production, 5x10^6 293T Lenti-X cells (Takara) 
were plated into 10 cm cell culture dishes and cultured o/n at 37 °C. At the next day, 5.1 
µg lentiguide-puro or cherry plasmid (addgene, #52963 and #99154, respectively), 4.3 µg 
psPAX2 (Addgene, #12260), and 1.3 µg pMD2.G (Addgene, #12259) were transfected 
using JetPrime transfection reagent (Polyplus transfection) according to the manufacturer’s 
instructions. Transfection medium was changed after 4 h to 10 ml normal growth medium. 
Supernatant was collected 24 h, 48 h, and 72 h after transfection, centrifuged at 300 x g for 
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10 min, filtered (.45 µm) and concentrated using Lenti-X concentrator (Takara; 100x 
concentration). 0.5x10^6 THP-1 cells were transduced using 5 µg/ml polybrene 
(Thermofisher #TR-1003-G) and 50 µl of concentrated lentivirus. To excise exon 1 of 
LUCAT1, a combination of two gRNAs (5’-agattgccacagacaccca-3’ and 5’-
aattggttcagcatctacca-3’) was used. 24 h post induction, 40 µg/ml puromycin (Thermo 
Fisher) were added to cells and antibiotic selection was performed for 1 week. Limiting 
dilution was used to generate clonal cell lines. Excision of LUCAT1 was checked using 
standard PCR with genomic DNA targeting LUCAT1 exon 1 (check primer, fwd.: 5-
ctcccataaccctttgaagcct-3’; rev: 5’-gagccaagatcacaccactgta-3’). 
 
RNAseq and ChIPseq analysis 
One million of A549 cells silenced or not for Nrf2 using siRNA were snap-frozen on dry 
ice. RNA extraction, library preparation, RNAseq and bioinformatics analysis was 
performed at Active Motif (Carlsbad, California, USA).  Briefly, the sequencing reads 
were aligned to human genome (version  Hg19) and the resulting binary alignment (BAM) 
files were used to calculate the gene counts that represent total number of sequencing reads 
aligned to a gene. To identify differentially expressed genes between control and Nrf2 
siRNA-treated samples, DESeq2 algorithm was used [249]. The list of differentially 
expressed genes from DESeq2 output were selected based on 10% adjusted P-value level 
and an FDR of 0.1.  Among these, the highly significant genes (FDR < 10%) genes were 
selected that are involved in pattern recognition signaling, antiviral signaling and 
experimentally identified Nrf2 transcriptional targets [250-252]. To depict these genes as 
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heatmap, count data was transformed using regularized-logarithm transformation 
(rld)[249]and the resulting values were mean-centered and plotted using heat map package 
available in bioconductor repository (Raivo Kolde (2015). Heat map: Pretty Heatmaps. R 
package version1.0.8. http://CRAN.R-project.org/package=pheatmap). Gene ontology and 
KEGG pathway enrichment analysis was done using DAVID bioinformatics resources 
portal [247]. 
Data availability 
GSE113522 is the reference Series for both ChIP-seq and RNA seq: 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113522] 
 SubSeries that are linked to GSE113522: 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113497] 
[https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113519] 
 Short-interfering RNA (siRNA)-mediated knock down 
For short interfering RNA experiments, A549 were transfected in 6-well plates with 80 
pmol of human Nrf2(1) (sc-37030), Nrf2(2) (sc-44332) or control si RNA (sc-37007) 
diluted in serum and antibiotic free DMEM and using Lipofectamine RNAi Max as per 
manufacturer’s instructions. A549 were incubated for 48h in the presence of the siRNA 
before being processed. 
For the Nrf2-gene RNAi screening experiment, A549 cells were transfected in 6-well plates 
with 80 pmol of a cherry-pick RNAi library from Dharmacon. siRNA sequences were 
diluted in serum and antibiotic free DMEM and transfected using Lipofectamine RNAi 
Max as per manufacturer’s instructions.  
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For gene interference in primary human monocyte-derived macrophages (hMDMs), cells 
were transfected on day 6 and 8 post isolation in 48-well plates with a pool of Nrf2 specific 
siRNAs (sc-37030), or siRNA controls (30 nM) using Lipofectamine RNAiMax (Life 
















Revisiting thesis objectives 
 
Innate immune system, first line of defense, once activated launches an extensive 
inflammatory response resulting in ligation of receptors, post translational modification of 
adapter proteins, induction of pro-inflammatory gene program, activation of adaptive 
immunity and lastly expression of negative regulators, for effective pathogen clearance and 
return to homeostasis. Fine tuning of activation, duration and suppression of immune 
responses is manifold and involves coordination of a myriad of protein and non-coding 
players including lncRNAs. As I have extensively described in previous chapters, 
expression of lncRNAs are co-induced upon host-pathogen mediated activation of immune 
genes. Although, innate immunology field is saturated with the study of protein molecules 
playing role in immune responses, identification and characterization of lncRNAs expands 
the scope of novel regulators of these responses. Given the poor cross-species conservation 
of most lncRNAs, specie specific and cell specific interrogation of biological systems is 
crucial for an in-depth understanding of its role in cellular signaling. The goal of this study 
was identification of novel non-coding regulators influencing host-pathogen interaction in 
human cells.  
In this study, we describe a lncRNA LUCAT1 as a dynamically regulated gene 
which functions as a potent regulator of IFN-I responses in human immune cells. LUCAT1 
was first identified as Smoke and Cancer Associated lncRNA-1 (SCAL1) in lung cancer 
cells. LUCAT-1/SCAL1 is induced upon exposure of human lung cell lines to cigarette 
smoke in a KEAP1-NRF2-dependent manner and shown to protect cells from oxidative 
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stress [215]. Since this initial discovery, LUCAT1 has been associated with various forms 
of cancer and plays a pivotal role in tumorigenesis by promoting cell migration[216], cell 
proliferation [217], and metastasis[216, 218-220]. Furthermore, LUCAT1 was shown to 
be highly upregulated in retinal muller glial cells upon Toxoplasma gondii infection 
indicating a potential role in immune responses [221]. Using high throughput RNA-
sequencing, we identified LUCAT1 as one of the strongest induced lncRNAs in LPS-
stimulated or virus-infected human dendritic cells (DCs). Genetic ablation of LUCAT1 
using virus-like particles loaded with Cas9 and sgRNA, so-called Nanoblades, resulted in 
hyperactivation of ISGs and pro-inflammatory cytokines in the human monocytic cell line 
THP-1 as well as in primary human DCs. Accordingly, overexpression of LUCAT1 in 
THP-1 cells using CRISPR activation (CRISPRa) attenuated the inducible IFN-I response. 
LUCAT1 interacts with STAT1 in the nucleus and in so doing restrains ISG expression. 
The inducible expression of LUCAT1 is therefore a post-induction feedback regulatory 
mechanism to limit the magnitude and duration of the IFN response.  
As previously emphasized, lncRNA conservation across species is poor but not 
limited to sequence homology. The secondary structure of lncRNAs are crucial for 
imparting their specific biological function. Additionally, many lncRNAs are conserved 
syntenically across species, i.e., their function with respect to genomic location and 
proximity to neighboring genes is conserved. Following lncRNA specific characteristics 
for conservation, we performed sequence homology analysis to identify mouse homolog 
of human LUCAT1. Interestingly, mouse LUCAT1 (mLUCAT1), annotated as 
5430425k12RiK  shared ~50% genomic and ~80% homology at mRNA level with the 
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human LUCAT1 (This has been described in detail in Appendix II). Moreover, similar to 
human LUCAT1, mLUCAT1 was syntenically conserved by being downstream of 
ARRDC3. Upon evaluation of mLUCAT1 levels in murine macrophages cell line, 
RAW264.7, we observed an induction of mLUCAT1 at 2hr with LPS stimulation, similar 
to human LUCAT1. Furthermore, mLUCAT1 was highly expressed lung tissues, similar 
to human LUCAT1 whose expression is highest in lung tissues with various conditions 
such as cancer and oxidative stress. Following these observations, we decided to generate 






Figure 3.2: Activation of LUCAT1 upon immune cell stimulation.  
Immune activation, specifically TLR4 signaling induces expression of inflammatory 
cytokines, simultaneously upregulating LUCAT1 expression. Nuclear enriched LUCAT1 
in turn acts as a post induction feedback negative regulator of ISG expression, by 





Proposed nuclear function of lncRNA LUCAT1 
 
 STAT1 is the master regulator of type-I interferon signal transduction pathway and 
functions downstream of the heteromeric IFNAR receptor to induce expression of several 
ISGs. From interaction with the surface receptor to binding to DNA in the nucleus, STAT1 
performs multiple functions crucial for activation and maintenance of this pathway, 
restating the importance of STAT1 in IFN-I signaling. In stimulated cells, the prompt 
induction of STAT1 is also accompanied by its rapid decay which is crucial for avoiding 
undesired and persistent inflammatory gene signature.  Given the central role of STAT1 in 
IFN-1 pathway, its regulation of activation and suppression is also regulated by several 
mechanisms. LUCAT1 acts as negative regulator of IFN-I and loss of LUCAT1 promotes 
increased and sustained STAT1 activation leading to hyper induction of ISGs. 
Additionally, LUCAT1 is associated with the chromatin. Together with the impact on gene 
expression and its direct association with nuclear STAT1, it is suggestive that LUCAT1 is 
regulating STAT1 function to suppress gene expression. The exact mechanism of action is 
not completely understood but based on our current knowledge on STAT1 function and its 
association with LUCAT1, the potential mechanisms are discussed below. 
 LUCAT1 pulldown using ChIRP in stimulated THP-1 cells, showed enrichment of 
several proteins that function as splicing factors as compared to control samples. Amongst 
the interacting proteins, hnRNPc, also known as AUF1 showed higher enrichment in 
LUCAT1 pull down samples. hnRNPc is an RNA binding protein and in involved in 
various mRNA processing pathways such as splicing [253, 254], 3’ polyadenylation [255]  
and stability [256]. In cancer models, hnRNPc has been shown to play a role in proliferation 
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and tumorigenesis by modulating IFN-1 interferon response against dsRNA, implying its 
immune role as well [257]. Immune relevance of hnRNPc  was demonstrated in a study by 
Yu-Lu et al. showed that AUF1/hnRNPc null mice succumb to cytotoxic shock and display 
high mortality and systemic hemorrhaging due to excessive production of inflammatory 
cytokines [258].  hnRNPc functions as a repressor of inflammatory genes by targeting their 
mRNA for degradation [257]. Therefore, loss of hnRNPc results in excessive transcripts 
thereby resulting in a cytokine storm. The finding of this study corroborates with that of 
LUCAT1 depletion in monocytic cells. Given, LUCAT1 binding to hnRNPc is bonafide, 
alternative splicing and mRNA degradation of inflammatory genes can be a potential novel 
mechanism of action of LUCAT1.  
 Activation of gene transcription is initiated by cooperative assembly of 
transcriptional factors at the promoter. It is now fairly understood that lncRNAs exert their 
function by association in protein complexes. Activated STAT1-IRF9 ternary complex 
binding to ISRE sequence on DNA can potentially involve LUCAT1 association. Binding 
of LUCAT1 to STAT1 at the promoters of ISGs can displace transcriptional activators  
factors, thus down regulating the target gene expression. Thus, LUCAT1 can function as a 
decoy for STAT1 target genes, to restrict its binding to the chromatin and promoting 
suppression of ISGs. Complex formation of LUCAT1 RNA-protein interactions meet the 
criteria of regulatory units. LncRNA Thrill and lncRNA EPS forms functional complexes 
with hnRNPL at the promoter region to regulate IRG expression [150, 156]. Therefore, 
lncRNA interaction with hnRNPs in a complex to attenuate STAT1 transcriptional activity. 
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 Furthermore, STAT1 binding to DNA in a sequence specific manner is crucial to 
promote cytokine driven gene regulation. STAT1 interaction with DNA phosphodiester 
backbone is mediated by specific residues such as Asp460, Lys336 and Glu421 in the DNA 
binding domain of STAT1 [259]. Association of LUCAT1 with STAT1 can potentially 
block the DNA binding residues on STAT1 to create a stearic hindrance and preventing 
gene expression. In a similar manner, lncDC associates with STAT3 to prevent 
dephosphorylation by SHP1. Contrarily, LUCAT1 can associate with STAT1 to promote 
its inactivation. Structural analysis and targeted mutagenesis of LUCAT1 and STAT1 
binding can reveal if LUCAT1 is sterically inhibiting STAT1 association with the DNA to 
suppress gene expression LUCAT1 can act as transcriptional interference or a  scaffolding 
complex to control STAT1 mediated gene expression. 
 Given the importance of PRC2 and TrxG complex protein in regulation of gene 
transcription as discussed in detail in section 1.5, RNA immunoprecipitation of PRC2 
complex demonstrated association of several lncRNAs with EzH2 subunit, thus 
emphasizing the roles of lncRNA-PRC2 mediated gene regulation [260]. lncRNAs binding 
to the EED domain of PRC2 recruit H3K27me to the target genes to down regulate gene 
transcription. In stimulated conditions, induction of LUCAT1 promotes a negative 
feedback loop for downregulation of IFN-I response. The impact of LUCAT1 on promoter 
occupancy of H3K4me3 and polymerase II suggests transcriptional feedback role of 
LUCAT1. Similar to several other nuclear localized lncRNAs, it is likely that LUCAT1 
forms complexes with chromatin in association with other proteins or transcription factors 
under stimulated conditions.  Interestingly, IFN response is epigenetically regulated 
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through di-methylation of histone 3 lysine 9 by. As a nuclear lncRNA, LUCAT1 can 
possibly modulate epigenetic marks or other chromatin marks on the ISG loci. Most 
lncRNAs have been found to exert modulatory effect by associating with the PRC2 
complex protein such as EZH2 and recruiting H3K to negatively regulate gene 
transcription. Although, it has been suggested that lncRNA interaction with PRC2 complex 
may be non-specific attributing to the high abundance and ubiquitous binding of EZH2 
with many genes., many lncRNAs such as Morrbid promotes PRC2 enrichment at the 
promoter of Bim and enhancing PRC2 occupancy leading to H3K27me3 mediated 
suppression of gene transcription[213].  LUCAT1 promotes suppression of immune 
response by associating with STAT1 in the nucleus. 
Alternatively, LUCAT1 may inhibit STAT1 mediated transcription through non-
epigenetic mechanisms. Following STAT1 nuclear import and gene activation, 
conformational changes in STAT1 makes it highly susceptible to dephosphorylation by 
nuclear dephosphatases such as T- cell protein tyrosine phosphatases (Tc45). Therefore, 
LUCAT1 can potentially recruit dephosphatases to the STAT1 for downregulation of its 
function there by restricting ISG expression.  
  
Transcriptional regulation of lncRNA LUCAT1 
LUCAT1 was initially discovered in lung cancer cells and was transcriptionally 
upregulated in response to cigarette smoke by nuclear factor erythroid 2-related 
factor NRF2 [215] . In resting cells, LUCAT1 is expressed at low copy numbers and gets 
rapidly induced in stimulated conditions to regulate type-I IFN, as discussed in previous 
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section. Given the differential expression and function of lncRNAs in different cells, we 
tested the role of NRF2 on LUCAT1 expression in primary human cells. Indeed, LUCAT1 
expression was significantly abrogated in NRF2 depleted primary macrophages. 
Furthermore, NRF2 occupancy, as determined by ChIP seq in THP-1 cells confirmed 
NRF2 dependent gene expression of LUCAT1 in human myeloid cells.  
Many studies have shown role of NRF2 in anti-inflammatory pathways in cells. 
NRF2 belongs to oxidative stress pathway and is kept in inactive state by association with 
KEAP1 protein. A recent study by Millis et al suggests that post translational alkylation of 
KEAP1 releases NRF2 in LPS stimulated cells. Further, KEAP1 was shown to be alkylated 
by a Krebs cycle intermediate, itaconate released as a product of conversion of aconitate to 
citrate. The anti-inflammatory effect of metabolite through NRF2 pathway is intriguing 
however, how NRF2 regulates inflammatory gene expression is not completely 
understood. Given NRF2 dependent induction of LUCAT1, we were intrigued to explore 
the function of LUCAT1 in itaconate-NRF2 pathway. Primary cells treated with a cell 
permeable form of Itaconate, i.e. 4-OI showed induction of LUCAT1 which was lost in 
NRF2 depleted cells. Moreover, pre-treatment of cells with 4-OI reduced the inflammatory 
response of LPS. Together, these data suggest that LUCAT1 is downstream of NRF2 
pathway and is induced by metabolite, Itaconate. However, a direct correlation of itaconate 
in regulation of NRF2-LUCAT1 mediated inducible anti-inflammatory gene program 
needs to be established. Interestingly, many recent studies have reported metabolic 
reprogramming of cells during an immune event. Identification of lncRNA, such as 
LUCAT1 increases our understanding of a novel mechanism at the cross section of 
 144 
metabolic regulation of immune responses.  Further work on this aspect of immune 
regulation would not only enhance our understanding of novel cross talk between two 
prominent pathways, metabolism and immune response but also identifies lncRNAs to be 
at the intersection of metabolically regulated inflammatory responses.  
 
 
Impact of NRF2 on NFκB pathway 
 
General consensus in the field states that transcription factor NRF2, is the master 
regulator of oxidative genes to combat cellular ROS levels and to protect cells from 
cytotoxic stress. The contribution of NRF2 in immune pathways is still evolving, with 
evidence suggesting that NRF2 can act as negative regulator of IFN-I and NFκB response 
in murine models. Gunderstofte et. al. reported that NRF2 null mice exhibit increased IFN-
1 genes , an observation consistent with decreased Herpes Virus replication [261]. 
Additionally, NRF2 also regulates NFκB dependent genes by directly binding to the 
promoter of IL6 and suppressing its expression. This inhibition is mediated by restricting 
binding of polymerase II, thereby abrogating the transcriptional activation of IL6 [262]. 
These and many other studies have identified role of NRF2 in immune responses, 
specifically in NFκB pathway, however the mechanism of NRF2-NFκB interplay still 
remains to be fully understood.  Given, that LUCAT1 is a NRF2 response gene and is also 
highly induced by LPS stimulation in primary human DCs and macrophages, there is a 
possibility that NRF2 mediates its anti-inflammatory role via LUCAT1 induction. Since 
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LUCAT1 depletion results in a hyper inflammatory gene signature including both IFN-I 
and NFκB dependent pro-inflammatory genes, direct interaction of both LUCAT1 and 
NRF2 at the promoters of these genes might act as a transcriptional break for suppression 




Figure 3.1: Metabolic control of LUCAT1 expression.  
LPS signaling upregulates ISG, IRG1 gene which converts TCA cycle intermediate cis-
Aconitate to Itaconate in the mitochondria. Cytosolic itaconate mediates proteasomal 
degradation of KEAP1, activating NRF2. In the nucleus, NRF2 binds to LUCAT1 






Working model of lncRNA LUCAT1 function 
LncRNA LUCAT1 is  a post induction feedback negative regulator of type-1 
interferon responses, and its association with STAT1 can modulate ISG expression by the 
proposed mechanisms discussed in the above section. According to our observations, wild 
type cells upregulate lncRNA LUCAT1 in response to pathogenic ligands by binding to 
surface and cytosolic receptors. Furthermore, LUCAT1 upregulation is facilitated by Krebs 
cycle metabolite, itaconate that releases NRF2 from KEAP1, activating NRF2, which in 
turn transcriptionally induces LUCAT1 expression. Increased levels of LUCAT1 in the 
nucleus associates with STAT1 protein to quench it thereby attenuating ISG expression as 
depicted in Figure 3.3. In absence of LUCAT1, STAT1 protein does not bind to LUCAT1 








Figure 3.3: Model of LUCAT1/STAT1 Interaction.  
LUCAT1 binding to STAT1 can mediate transcriptional regulation ISG expression by 
various mechanisms: 1. Sequestering STAT1 and inhibiting its binding to the promoters of 
IFNb and ISGs. 2. Recruitment of PRC2 complex mediating histone modifications and 
downregulating gene expression. 3. Inhibiting binding of transcriptional activators such as 




Isoforms and splicing of lncRNAs 
 
LncRNA studies are challenged to resolve the gene structure accurately to 
determine 5’ and 3’ transcriptional sites. And often, we find transcription of multiple 
isoforms such as lncRNA LUCAT1, generated from the lncRNA gene locus, mostly 
differing in their 3’ends. Such results give rise to inevitable impending question to 
determine the true functional isoform contributing to the biological phenotype. This 
involves extensive use molecular and computational approaches to study the role of each 
isoform in the biological context. Nonetheless, most lncRNAs have multiple isoforms with 
overlapping functions, thus delineating the role of one functional isoform more 
challenging.  The abundance of lncRNA isoforms exceeds that of protein coding mRNAs 
and studying mechanisms that give rise to diversity in isoforms will enhance our 
understanding of their cell specific transcriptional regulation. 
Genes encoding lncRNAs exhibit diversity in the cleavage of 3’ends resulting in 
transcription of multiple isoforms from a given lncRNA locus. In addition to overlapping 
and embedded sequences, and poor annotation of exons and introns, complexity of lncRNA 
locus is also influenced by variation in transcription initiation and termination sites.  
Alternative cleavage and polyadenylation sites (APA) in lncRNA genes can contribute to 
alternative 3’ends resulting in diversity of lncRNA isoforms. Majority of human lncRNA 
genes undergoing APA have alternative polyadenylation sites upstream of last exon, 
whereas in mRNAs the alternative polyA sites are within the most 3’ exon. Given the poor 
conservation of lncRNA sequences, up to 45% of conserved lncRNA sequences are located 
downstream of the last polyA site thus contributing to the heterogeneity in 3’ splicing sites 
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[263]. Interestingly, lncRNAs undergoing APA can have retention or elimination of 
specific nucleic acid sequence motifs that can redirect their localization to different 
compartments of the cell. For example, LUCAT1 has more than 15 isoforms and various 
studies place LUCAT1 in various subcellular compartments, however that is specific to the 
isoform being studied.  
In addition of APA, 3’ post transcription processing also generates alternative 3’ 
ends and increases the repertoire of lncRNA isoforms. MALAT nascent transcript 
undergoes a RNAseP mediated 3’ cleavage downstream of the bonafide polyA site, 
generating an alternative 3’ end for MALAT1 and a 5’ start site for a tRNA like 
cytoplasmic MALAT1 isoform [264]. Additionally, it is suggested that lncRNAs use 
alternative transcription start site generating more diversity in the isoforms of lncRNAs 
transcribed from a given locus.  
 
Dysregulation of LUCAT1 in Immune Disorders  
 
Many human diseases are characterized by a disbalance in immune responses, 
either resulting in surplus of inflammatory signals like in autoimmune disorders or 
inadequate cytokine levels as characterized by several bacterial and virus infection 
resulting in complicated conditions including sepsis.  
 LUCAT1 is a potent negative regulator of type-1 interferon responses and loss of 
which results in cytokine storm as characterized by many autoimmune disorders such as 
Lupus, Irritable bowel diseases, crohn’s disease and others that display a dysregulation of 
interferon responses. Such interferon driven disorders might be correlated with reduced or 
altered levels of negative regulators such as LUCAT1. Therapeutic expression of LUCAT1 
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in such disorders can promote a reversal of hyper-inflammatory state. This can provide 
novel approaches to clinically target lncRNAs such as LUCAT1 for therapeutic 
interventions as discussed below. Additionally, targeting LUCAT1 in infectious diseases 
can result in enhanced cytokine response, beneficial for pathogen clearance. 
 
LUCAT1 as a Therapeutic Target 
 
Human gene therapy is a modern intervention to compensate for loss or gain of 
genetic variations for treating underlying acquired and genetic disorders.  Although, human 
gene therapy is a continuously evolving therapeutic area, many diseases such as arthritis, 
cancer, neurodegenerative diseases and AIDS have been successfully intervened using 
gene therapies [265].  Gene therapy employs the use of both viral and non-viral based 
approaches such as AAV gene therapy and liposomes, polymers and dendrimers for 
expressing and targeting genes and can be applied for most genes with the promise of 
lncRNAs.  
 
 lncRNAs can fine tune host pathogen interaction using diverse mode of actions. 
This creates a number of strategic approaches for therapeutically targeting lncRNAs 
implicated in diseases. LncRNAs can be targeted post transcriptionally using RNAi and 
ASO approaches as discussed in section 1.9. Further, the inhibition of lncRNA 
transcription by blocking promoters regions or directing transcriptional machinery away 
from lncRNA locus may also be used as an indirect mode of targeting the lncRNAs. 
Finally, lncRNA functions can be targeted by perturbing their interactions with protein 
complexes. 
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 While there have been several clinically approved nucleic acid based therapies as 
described in previous sections with successful disease intervention, they have some 
limitations. Foremost, absorption (passive or active) of antisense oligos across the plasma 
membrane has always been challenging and poses a limitation on the success of nucleic 
based therapies.  Foreign nucleic acids are immune-stimulatory molecules that can be 
detected by various TLR and cytosolic nucleic acids sensor pathways to elicit a pro-
inflammatory gene program and may result in degradation or neutralization of nucleic-acid 
drug molecules. Additionally, endocytosis of nucleic acid drug molecules can result in their 
degradation and subsequent reduction in bioavailability and lastly as with every therapy, 
lowering toxicity and off target effects simultaneously maximizing efficient targeting is the 
goal towards lncRNA therapies. The application of CRISPR technology for lncRNA 
targeting overcomes several shortcomings of nucleic acid based therapies, thus opening 
novel approaches to lncRNA based drug discovery. Overall, lncRNA based drug discovery 












Characterization of murine homolog of human 
lncRNA LUCAT1, 5430425K12RiK and 
generation of  mLUCAT1 transgenic mouse 
 
 
Preface to Appendix II 
This project was done in collaboration with Dr. Zhaozhao Jiang and Dr. Tim Vierbuchen 





Functional characterization of lncRNA LUCAT1 in human cells revealed a 
transcriptional role in regulation of Type-I IFN. Although, cell culture models provide in 
depth understanding of molecular mechanism of lncRNAs, in-vivo study provides a 
comprehensive systemic understanding of endogenous lncRNA function . General 
consensus in the field states poor conservation of lncRNAs however, lncRNAs contain 
short sequences that are found to be conserved by cross-species comparison of genomes 
[266, 267].  Additionally, lncRNA secondary structure drive lncRNA functions and 
studying higher-order conservation in lncRNAs might provide better understanding of 
conservation across species.  Therefore, identifying lncRNA conservation across species is 
multifactorial.  In order to further understand the implication of LUCAT role at systemic 
level, we sought out to identify a mouse homolog for human LUCAT1 gene. Several 
studies have eluded that genomic location of lncRNAs relative to protein coding genes 
might play role in driving their biological function. To this end we perform sequence 
homology and syntenic homology for hLUCAT1 in mouse genome. Bioinformatic analysis 
revealed a syntenically conserved mouse homolog for human LUCAT1 gene.  We have 






Culture and Treatment of Mouse RAW 264.7 Macrophages 
RAW 264.7 cells were cultured in growth media [DMEM supplemented with 
10% (v:v) FCS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin and 
incubated in a 37°C, 5% (v:v) CO2 humidified incubator. For all experiments, RAW cells 
were seeded in 24-well plate at 5 × 105 cell/well and stimulated with 1 µg/ml LPS  for 2 
to 24 h. 
RNA Isolation and RT-qPCR 
Total RNA was isolated using Aurum Total RNA mini kit (Bio-Rad Laboratories). 
RNA concentration was determined using a spectrophotometer (Nanodrop, Thermo Fisher) 
and RNA with an A260/A280 ratio >2.0 was considered as pure. RNA was reverse 
transcribed using iScript cDNA Synthesis Kit and quantitative PCR was performed using 
iTaq Universal SYBR green supermix (both Bio-Rad Laboratories) according to 
manufacturer’s instructions. Fold change in mRNA expression was calculated using the 
comparative cycle method (2^-dCT) normalized to the housekeeping gene GAPDH or 
HPRT. List of primer in Table 4 
mLUCAT1 RT-qPCR primers 
mLUCAT1686F CACAACGTATCCACCCTTCC 
mLUCAT1686R GTGTGCACATGCTCTCTCGT 





Transgenic mouse generation strategy 
We generated null allele of mouse lncRNA 5430425K12Rik (human gene 
LUCAT1) using CRISPR-cas9 system. We approached this by make deletion of entire 
transcript and designing guides upstream start and downstream final exon of the gene. 
Combinations of sgRNA were used to create large deletions which were co-injected with 
Cas9 mRNA + IDT Cas9 protein using a single cell embryo injection. gRNAs were selected 
to minimize off target cutting sites and maximize cutting efficiency. For entire mLUCAT1 
deletion (~8kb), we included a ssODN (i.e. oligo) donor (ultramer from IDT) to “bridge” 
the two cut sites. We incorporated 60bp homology arms upstream of 5p site and 
downstream of 3p site and an additional NotI site to distinguish between deletions using 
the oligo or just NHEJ.  
CRISPRseek analysis 
For designing sgRNA, 5p of first exon and 3p of last exon were searched in 
MmLUCAT1b.ape (see below) for SpCas9 sites. Search parameters included targeting 
mouse genome with max 3 mismatches for off-target using CFD score [268]  on target 
efficiency [269]. Based on the above criteria, following candidate sgRNAs were designed 
and injected.  
MmLUCAT1_5p_gR50f TGATTCAGTTCTGACTCAAGAGG, 
MmLUCAT1_5p_gR371r ACATTCAGATCGCTGGAGAGCGG, 
MmLUCAT13p2_gR266r GCATTACCAGACAGAAGGCGTGG and the genomic 
distance between 5p + 3p cut sites ~8kb. 
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Donor design 
For the 8kb deletion, it was recommended to include a ssODN (i.e. oligo) donor to 
“bridge” the two cut sites and increase. The donor was ordered from IDT as an “ultramer” 
which has 60bp homology arms upstream of 5p site and downstream of 3p site and a NotI 
site to distinguish between deletions using the oligo or just NHEJ. Predicted deletion plus 






















































Mouse: 5430425K12Rik;Long non-coding RNA; Location: Chromosome 13: 80,940,403-
80,948,597 
Human Homolog: LUCAT1 
 











NNNNN- Annotated first exon 
 











































Blastn analysis of human and mouse LUCAT1 sequence showed ~50% homology 
in the genomic sequence and ~80% homology at the mRNA level (Figure A2.1). In order 
to understand the inducibility of mLUCAT1 in murine models, we injected C57BL/6 
mice with LPS for 24hr followed by harvesting organs for RNA analysis. We observed 
that LUCAT1 was highly expressed in lungs and muscle tissues and to a lesser extend in 
spleen, however inducibility with LPS was only observed in small intestine and colon 
(Figure A2.2). Furthermore, mouse macrophage cell Raw 264.7 when challenged with 
LPS showed a time dependent induction of mLUCAT1 which followed a similar kinetics 
as IFNb gene expression (Figure A2.3 a,b). Based on syntenic conservation of 
hLUCAT1 with mLUCAT1 and its expression and inducibility in murine models, we 
generated a transgenic mouse with complete deletion of mLUCAT1 gene as described 
above.  Genotyping analysis of founder mice yielded 2 mice with complete excision of 
mLUCAT1 gene. The two founders are being backcrossed and further propagated to 










Figure A1.2: mLUCAT1 expression in mouse tissues 
 
a Mice were intraperitoneally injected with LPS and PBS as control. Organs were 
harvested for RNA isolation. RT-qPCR analysis of GAPDH and mLUCAT1 gene 






Figure A1.3: mLUCAT1 expression in RAW264.7 cells 
 
Mouse macrophage cell line RAW264.7 cells were treated with LPS in time course 
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Figure A1.4: Genotyping of mLUCAT1 founder mice. 
 
DNA obtained from injected C57BL/6 mice were genotyped using PCR. Agarose gel 
showing successful excision of mLUCAT1 mice in two founder mice (Mouse number 10 




In vivo models provide a powerful tool for interrogating gene function and a 
detailed functional characterization at systemic levels. Bioinformatic and in-vitro analysis 
of mLUCAT1 showed good homology to human LUCAT1 and inducibility to LPS 
respectively. Furthermore, expression of mLUCAT1 in lungs also correlates with high 
human LUCAT1 expression in lung. All these data provide promising evidence of 
mLUCAT1 to be a true homolog for human LUCAT1. Further, in vivo characterization of 
mice challenged with viruses and immuno stimulatory ligands can provide in depth 
understanding of effect of mLUCAT1 in regulation of immune responses at systemic 









Identification and Characterization of lncRNA 
IFI16 in immune responses. 
 
Preface to Appendix-III 




Long intergenic non-coding RNA (lincRNA) constitutes the largest class of 
lncRNAs and are located between protein coding genes, generally within 40Kb of protein 
coding genes. Given the crucial role of interferon stimulated genes in host pathogen 
interaction, we wanted to explore and characterize lincRNAs specifically located in the 
vicinity of ISGs. Aim2 and IFI16, both are members of PYHIN family of proteins or IFI200 
(Interferon inducible with a 200 amino acid repeat) and primarily function as DNA sensors. 
They are found in clusters and human locus contains a total of 4 genes namely AIM2, 
IFI16, IFIX and MNDA which is syntenically conserved in mouse cells with 13 PYHIN 
proteins (Fig. A3.1a-b). The mouse PYHIN proteins exceeds that human PYHIN proteins 
as a result of gene duplication events to give rise to multiple forms of PYHIN proteins, 
however the functions of PYHIN proteins in both species are mostly conserved [259]. 
Using data mining tools, our lab has identified an un-annotated intergenic region between 
AIM2 and IFI16 genes, which can be a putative lincRNA. Given the importance of this 
interferon stimulated gene locus, the identified intergenic sequence can possibly be 
regulating molecular events in an immune response. According to sequencing data 
available, this intergenic region has many Alu repeat elements, which is characteristic of 
lincRNA sequences. For now, we have named this intergenic region as lincIFI16 based on 
its proximity to the nearest protein-coding gene, i.e. IFI16. The goal of this project is to 















Figure A2.1: PYHIN family proteins and gene locus in mouse and humans. 
a Schematic of gene locus showing PYHIN proteins in mouse and human. b Schematic 
of 13 mouse and 4 human PYHIN protein with their domain. Adapted from Cridland et. 









Leukoreduction system (LRS) chambers from healthy donors were obtained from 
New York Biologics. Peripheral blood mononuclear cells (PBMCs) were obtained from 
LRS chambers by Lymphoprep density gradient centrifugation (Stemcell Technologies). 
CD14 positive monocytes were isolated from PBMCs by magnetic cell separation (MACS) 
using CD14 microbeads (Miltenyi). Purity of isolated CD14 positive cells was determined 
using flow cytometry. 
Cell culture 
THP-1 cell line was obtained from ATCC and maintained in RPMI 1640 (corning) 
supplemented with 10% FCS and 1% Pen/Strep and were differentiated into macrophages 
in the presence of 10 ng/ml phorbol-12-myristate acetate (PMA, Sigma) for 12-16 hours 
followed by media change and resting for up to 48 hours. CD14+ monocytes were 
differentiated into monocyte-derived Dendritic Cells (hMDDCs) using a cocktail of hIL-4 
and hGM-CSF (produced in 293T cells) in RPMI with 10% pooled human AB serum 
(Sigma) for 7-8 days.  
RNA Isolation and RT-qPCR 
Total RNA was isolated using Aurum Total RNA mini kit (Bio-Rad Laboratories). 
RNA concentration was determined using a spectrophotometer (Nanodrop, Thermo Fisher) 
and RNA with an A260/A280 ratio >2.0 was considered as pure. RNA was reverse 
transcribed using iScript cDNA Synthesis Kit and quantitative PCR was performed using 
iTaq Universal SYBR green supermix (both Bio-Rad Laboratories) according to 
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manufacturer’s instructions. Fold change in mRNA expression was calculated using the 
comparative cycle method (2^-dCT) normalized to the housekeeping gene GAPDH or 
HPRT.  
Loss of Function studies 
For RNA interference studies, short hairpin RNAs (shRNA) targeting lincIFI16 and 
non-targeting control shRNA were cloned into the pLKO vector( addgene #8453). 4 µg of 
pLKO were transfected into HEK293T cells together with packaging vectors 1 µg 
pxMD2.G (Addgene, #12259) and 3 µg psPAX2 (Addgene, #12260) in 10cm dishes using 
GeneJuice(Millipore, #70967-6). After, 48 and 72 hours the supernatant was collected 
added to 2 X 10^6  THP-1 cells for 48 hours in presence of 8µg/ml polybrene, followed by 
2µg/ml puromycin (Corning, 61-385-RA) selection for 4-5days.  
RNA fractionation 
THP-1 cells were fractionated into cytosolic and nuclear compartments using 
detergent lysis method (Tsai et al., 2010). RNA was purified from individual fractions 
using TRIzol (Ambion) and reverse transcribed with oligo-dT primers using the cDNA 
synthesis kit (Agilent), and subjected to qPCR analysis. Expressions of target genes in 
individual fractions were normalized to their expression level in the input RNA, which was 




Existing RNA sequencing data was analyzed and transcriptional reads were 
identified in the intergenic region between IFI16 and Aim2 gene in human cells. In order 
to determine the effect on lincIFI16 in activated immune cells and its association with 
adjoining genes; IFI16 and AIM2, we performed RT-qPCR in THP-1 cells and primary 
human DCs stimulated by various TLR ligands. Initial experiments revealed its 
upregulation upon bacterial or virus infection in human monocytic THP-1 cell lines and 
primary human DCs, which was consistent with IFI16 gene expression in stimulated 
conditions (Fig. A3.2).  
lncRNA localization is pertinent to determining biological function and 
mechanistic insights. IFI16 is predominantly present in the nucleus due to the presence of 
a nuclear localization signal (NLS); however, in stimulated conditions it was found that 
lincIFI16 is mostly found in cytosol. These results suggest that lincIFI16 operates from the 
cytosol to enhance interferon response in infectious conditions(Fig. A3.3a) 
To determine function of lincIFI16 and its effect on AIM2 and IFI16 genes, we 
generated lincIFI16 knock down cell lines by expression of short-hairpin RNA targeting 
lincIFI16 in THP-1 cells.  By performing loss of function and gain of function experiments 
in stimulated and unstimulated cells stimulated with LPS to see the effect of lincIFI16 on 





To elucidate mechanistic role of lincIFI16, (i) cross-linking experiments followed by pull 
down will be performed to identify binding partners of lincIFI16. The resulting targets can 
be identified using Mass Spec and RNA sequencing approaches. Identification of binding 
targets will elucidate the pathways that are affected by lincIFI16 function thus elucidating  
 
 
Figure A2.2: LincIFI16 is expressed and induced in human monocytic cells. 
a Genome browser showing IFI16-AIM2 locus and intergenic reads corresponding to 
lincIFI16. b RT-qPCR analysis of lincIFI16 gene expression in stimulated THP-1 cells in 
at 1hr and 6hr timepoints. c RT-qPCR analysis of lincIFI16 in LPS, IFN α/β and SeV 

























































Figure A2.3: LincIFI16 is enriched in cytosolic compartment upon activation 
a RT-qPCR analysis of HPRT and lincIFI16 gene expression in nuclear and cytoplasmic 
fractions in IFN stimulated THP-1 cells. b RT-qPCR analysis of lincIFI16 in GFP, 




























Basal expression of linc IFI16 expression in 



































Interferon stimulated genes are cytokines and chemokines that are upregulated in 
response to pathogenic stimuli. It is now fairly understood that lncRNAs are 
transcriptionally co-regulated in inflammatory responses. With the objective of discovering 
novel lincRNAs in existing datasets, we used data mining approaches to identify lincRNAs 
transcribed from intergenic regions of immune genes. One such lincRNA IFI16 is 
described that was transcriptionally induced between the IFI16 and AIM2 genes in human 
cells. Given the crucial role of PYHIN proteins, IFI16 and AIM2 in DNA sensing and 
activation of immune response, we decided to characterize lincIFI16 in immune responses. 
We observed induction of lincIFI16 in both human cell lines and primary human cells after 
stimulation with various immune ligands. Although, IFI16 functions as a DNA sensor in 
the nucleus, lincIFI16 was found to be localized in the cytoplasm in the stimulated THP-1 
cells. Together these results suggests that lincIFI16 is a putative lincRNA and might have 
function in regulating DNA sensing pathways, however a detailed characterization needs 
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